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Abstract 
Human parturition involves interaction of hormonal, neurological, mechanical stretch and 
inflammatory pathways and the placenta plays a crucial role. The paraoxonases (PONs 1-
3) protect against oxidative damage and lipid peroxidation, modulation of endoplasmic 
reticulum stress and regulation of apoptosis. Nothing is known about the role of PON2 in 
the placenta and labour. Since PON2 plays a role in oxidative stress and inflammation, 
both features of labour, the hypothesis was that placental PON2 expression would alter 
during labour. PON2 was examined in placentas obtained from women who delivered by 
caesarean section and were not in labour and compared to the equivalent zone of placentas 
obtained from women who delivered vaginally following an uncomplicated labour. 
Samples were obtained from 12 sites within each placenta: 4 equally spaced apart pieces 
were sampled from the inner, middle and outer placental regions. PON2 expression was 
investigated by Western blotting and real time PCR. Two PON2 forms, one at 62 kDa and 
one at 43 kDa were found in all samples. No difference in protein expression of either 
isoform was found between the three sites in either the labour or non-labour group. At the 
middle site there was a highly significant decrease in PON2 expression in the labour group 
when compared to the non-labour group for both the 62 kDa form (p = 0.02) and the 43 kDa 
form (p = 0.006). No spatial differences were found within placentas at the mRNA level in 
either labour or non-labour. There was, paradoxically, an increase in PON2 mRNA in the 
labour group at the middle site only. This is the first report to describe changes in PON2 in 
the placenta in labour. The physiological and pathological significance of these remains to 
be elucidated but since PON2 is anti-inflammatory further studies are warranted to 
understand its role. 
 
Pre-eclampsia (PE) is associated with maternal and placental oxidative stress. The second 
aim was to determine the expression of PON2 in the placenta in pre-eclampsia. PON2 was 
examined in placentas obtained from non-labouring women who delivered by caesarean 
section (normal pregnancy and pre-eclampsia) and compared to women who delivered 
vaginally (normal pregnancy and pre-eclampsia).  Samples were obtained from 8 sites 
within each placenta: Four equally spaced apart pieces were sampled from the inner and 4 
from the middle regions. PON2 expression was investigated by Western blotting and qRT-
PCR. Two PON2 bands (62 kDa and 43 kDa were found in all samples. When PON2 
expression in the non-labour control group was compared to the non-labour PE group at 
the inner placental site no differences were found. At the middle placental site a reduction 
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in both PON2 isoforms was observed in the non-labour PE group compared to the non-
labour control group (p=0.02 for both isoforms). No difference was found between labour 
control and labour PE at the inner site. A reduction in PON2 was observed in the labour PE 
group compared to the labour control group (PON2 62 kDa p=0.008, PON2 43kDa 
p=0.001). No differences in mRNA were found. Conclusion: This is the first study to 
investigate the expression of PON2 in PE. Given the protective roles of paraoxonases 
future studies including measurement of PONs in maternal blood, PONs gene 
polymorphism and paraoxanase induction experiment on this family of proteins may reveal 
new insights into understanding PE. 
The third aim was to perform the same experiments as above but for PON3. There was no 
difference in expression of PON3 between the three sites (inner, middle, outer) within 
individual placentas for both labour and non-labour. PON3 was significantly decreased in 
the labour group when compared to the non-labour group at the inner site.  No other 
differences were found. There was a significant decrease in PON3 expression in the PE 
non-labour group compared to the control non-labour group in the middle site only. There 
was a significant decrease in the PE labour group compared to the control labour at the 
middle site only. 
 
Finally preliminary experiments were performed to determine if different zones of the 
placenta were more susceptible to ischemic-reperfusion injury in vitro. The number of 
experiments was not sufficient to make definitive conclusions but the pilot data suggest 
this should be explored more in future studies include more placenta tissue exposed to 
ischemic-reperfusion injury to understand how placental stress might affect placental 
function. 
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1 Introduction  
1.1 The placenta  
1.1.1 Anatomy 
The human placenta connects the growing fetus to the uterine wall and allows transfer of 
nutrients, prevents immune rejection, eliminates fetal waste and secretes hormones that 
support the pregnancy. The placenta is a disc shape organ, weighing on an average about 
470 g (Berirschke et al., 2006). In early pregnancy the placenta is formed from the union 
of the chorion and the allantois. The pregnancy endometrium is named decidua and the 
attachment site of the placenta to the uterus is called the decidua basalis or basal plate 
(maternal surface) Figure 1.1 A and B. 
 
 
Figure 1-1: Illustration of the term human placenta. The upper shows the fetal side of the 
placenta. The umbilical cord inserts within the chorionic plate. The lower shows the 
maternal side which is contact with uterus and divided into cotyledons. 
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Figure 1-2: Structure of human placental: A- Diagram of human placenta shows the 
umbilical cord and longitudinal section of placenta. B- Magnified view of full thickness of 
human placenta showing the fetal and maternal sides. Figure adapted from 
http://www.embryology.ch/anglais/fplacenta/villosite01.html 
 
The placenta is made of about 10-40 irregular shaped lobules named cotyledons. Major 
branches of the umbilical circulation supple each cotyledon. Cotyledon shapes are defined 
by placental setae. Cotyledons consist of villous trees structures that are bathed in maternal 
blood. The chorionic plate is the fetal surface where the umbilical cord inserts eccentrically 
in most placentas. The umbilical cord contains two arteries and one vein. The amnion faces 
the fetus and forms single layer of epithelium with basement membrane and avascular 
connective tissue base (Rampersad et al., 2011). The vessels that spread over amnion 
surface are chorionic vessels.  
 
 
1.1.2 Early developmental stages of placenta 
1.1.2.1 Stage of Pre-implantation:  
Decidualization is endometrium changes in structure in anticipation of implantation. After 
fertilization the fertilized egg called zygote, which transported through the fallopian tube to 
the uterine cavity, a process of 3-4 days. In fallopian tube the zygote undergoes a series of 
mitotic division to form a ball of cells called a morula, which after entry into the uterine 
cavity developed to a blastocyst. The blastocyst is formed of a fluid filled cavity 
surrounding by differentiated trophoblast forming a single layer of mononucleotide 
trophoblasts called the trophectoderm that forms the extraembryonic membrane and 
placenta. At one end of blastocyst there is an asymmetric group of cells forms the inner 
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cell mass that develop into the fetus (Boyd and Hamilton, 1970; Barnea et al., 1992; 
Benirschke and Kaufmann, 2000).  
 
1.1.2.2 Pre-lacunar stage: 
For successful pregnancy, implantation of blastocyst to the uterine wall must occur. The 
pre-lacunar stage begins on day 7 post conception as microvilli emanating from 
trophectoderm; these microvilli make the initial contact with uterus epithelium. 
Attachment of the blastocyst follows soon through a complex interplay between both the 
decidua and trophoblast cells. Apposition of blastocyst is the first step in implantation 
followed by an adhesion step, in which blastocyst adhesion to decidua with inner cell mass 
(Schlafke and Enders, 1975). The blastocyst thereby undergoes interstitial implantation 
within connective tissue and close to maternal blood vessels that will provide the blood 
flow to the placenta. During invasion of the blastocyst the cytotrophoblast proliferate and 
fuse to form double layer, with outer cells forming of differentiated multinucleated 
syncytiotrophoblast that comes in direct contact with the maternal tissue.  6 to 7 days post-
conception the embryo embedded in the uterus and epithelial cells grow over the site of 
implantation (Hertig et al., 1956). The inner cell mass also differentiates into bilaminar 
disk of embryoblast and amnioblast (Rampersad et al., 2011).  
 
1.1.2.3 Lacunar stage: 
Following invasion, about eight days after conception, multiple vacuoles are formed inside 
the syncytiotrophoblast. These vacuoles coalesce to form lacunae. These spaces will 
eventually form the intervillous space. Erosion of maternal blood capillaries will fill the 
intervillous space with maternal blood. Placenta spiral arteries will undergo physiological 
changes include trophoblast invasion and wall destruction (Lyall, 2007). During the time of 
organogenesis the low oxygen environment protect the fetus from reactive oxygen species 
(Lyall, 2007). During the low oxygen period, nutrients necessary for embryo development 
are obtained from plasma filtrate and uterine glandular secretions in the intervillous space. 
At the end of first trimester feto-maternal exchange of oxygen and nutrients start after the 
spiral arterioles begin to perfuse the intervillous space (Hustin et al., 1988).  
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1.1.3 Villous tree developments 
Villi are finger like outgrowths of trophoblast that form the tree like structure and 
proliferate into the intervillous space. These are primary villi contain an outer layer of 
multinucleated syncytiotrophoblasts and mono-nucleated cytotrophoblasts. At 5 weeks of 
gestation the primary villi are invaded by allantoic mesenchyme derived from the 
embryoblast, they are now called secondary villi, from which the feto-placental blood 
vessels will develop. The villous core of the villi is known as stroma and is composed of a 
loose network of fibroblast cells and hofbauer cells. By 5-6 weeks of gestation the first 
signs of “vasculogenesis” are evident. All subsequent generations of vascularized villi are 
subclasses of these tertiary villi. Mesenchymal villi give rise to mature intermediate villi, 
from which terminal villi will sprout. Intermediate villi eventually become stem villi. 
Terminal villi formed from non-branching angiogenesis are the last to form vessels 
because they are in contact with the trophoblast to allow nutrients and oxygen exchange. 
The villious tree is established as villi develop throughout the placenta forming a complex 
network which supports the growing fetus by the maternal circulation. Term placenta 
contains 60-70 main stem villi each of which is at a centre of a villous tree; these main villi 
subdivide into 2-5 branches (Page, 1993). Final stem villi have a single arteriole and a 
venue and contain up to 10 capillaries. By term the area of exchange of the villi is about 14 
square meters (Martal and Cedard, 1993). 
 
 
1.1.4 Functions of the placenta 
The placenta play unique functions includes metabolism of many compounds and also part 
of the feto-maternal flux that supplies the fetal needs. The placenta performs maternal-fetal 
transport, hormone synthesis, is a barrier to vertical transmission of pathogens and an 
immunological interface (Illsely, 2011). 
 
1.1.4.1 Placental transport 
The placenta functions as a transport system where it transfers nutrients, ions, gases, water 
to the fetus and waste is also eliminated via placenta. Active transport systems deal with 
different plasma concentration of various molecules. As pregnancy continue the placenta 
grows too so as to increase blood flow into the placenta; this involves altered dimensions 
and surface area of the exchange barrier by formation of terminal villi and increased 
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number of microvilli on the syncytiotrophoblast surface and change in transport activity. 
Transport is inversely proportional to the thickness of the exchange barrier which 
decreases during gestation (Sibley et al., 1998),  
 
Placenta transport systems  
Maternal-fetal exchange across the placenta is reviewed in (Sibley and Boyd, 1988; Sibley 
et al., 1998; Illsely, 2011). Below are listed the different exchange methods in the placenta. 
 
1. Passive diffusion: oxygen, gases, urea and free fatty acids transport via the placenta 
is by passive diffusion. Specifically, oxygen transport between maternal spiral 
arteries and intervillous space (O2 concentration 90 mmHg). CO2 is brought back 
from the uterine vein (O2 concentration 30-45 mmHg) to the maternal circulation 
(O2 concentration 30mmHg). The umbilical artery carries out the de-oxygenated 
blood back to the intervillous space (17mmHg).  
 
2. Facilitated diffusion:  
The trans-membrane proteins embedded in the plasma membrane facilitate the rate 
of transport down a concentration gradient in an ATP independent fashion. For 
example, there is a family of 12 diffusion protein members facilitating glucose 
transport.  
 
3. Active transport:  
Active transport is ATP dependent and there are many carrier systems for this type 
of transport.  Amino acids are an example. 
 
4. Receptor transport:  
This system is mediated by endocytosis. Protein transport take place this way, 
however, protein transport by this way is very restricted except for IgG. Receptor 
mediated endocytosis-receptors on microvilli bind IgG- coated pits are formed 
which are nipped off and move to the cytoplasm. Lipid transport also occurs by 
receptor mediated endocytosis; maternal plasma lipoproteins are taken up by 
receptors. 
 
5. Ions- diffusion system: 
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Sodium-ion transport occurs via diffusion as well as sodium transporters (Na
+
/H
+
 
exchanger) and (Na
+
/K
+
 exchanger). Similarly, potassium diffusion occurs through 
potassium channels. Calcium diffusion occurs through calcium channels for 
example transient receptor potential vanilloid (TRPV family). 
 
1.1.4.2 Excretion function of placenta 
Uric acid, urea and creatinine are waste products that are transferred to the maternal 
circulation by placenta through diffusion  
 
1.1.4.3 Endocrine functions of the placenta (hormone synthesis) 
The placenta is a remarkable organ with diverse functions. It plays an important role as a 
secretory organ. Different hormones that are important for pregnancy are produced by the 
placenta, specifically, from the syncytial layer of chorionic villi. The placenta produces 
many hormones and proteins such as hormones, human chorionic gonadotropin (hCG), 
oestrogens, progesterone, human placental lactogen (hPL), human placental growth 
hormone (hPGH) (Lacroix et al., 2002). The placenta also secretes others peptide 
hormones such as oxytocin, inhibin, Corticotrophin-releasing hormone (CRH) and 
prolactin. It also produces many growth factors that promote uterine blood flow and 
placental development such as vascular endothelial growth factor (VEGF), placental 
growth factor (PlGF), epidermal growth factor (EGF), and transforming growth factor 
(TGF).  
 Human chorionic gonadotrophin (HCG): 
HCG is a glycoprotein has a molecular weight of approximately 38,000 Dalton with 237 
amino acids organized in two dissimilar non-covalently linked subunits designated alpha 
(α) and beta (β) (Wu et al., 1994). HCG is produced in the syncytium and acts on 
Luteinizing hormone (LH) receptors. A critical role of hCG is to maintain and stimulates 
the corpus luteum (in the ovary) to produce progesterone. Additionally, hCG suppresses 
the maternal immune response to prevent fetal rejection. In the case of a male fetus, it 
stimulates fetal leydig cells to produce testosterone in order to affect male sexual 
development (Kay et al., 2011). 
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 Estrogen 
Placenta production of estrogen is dependent on maternal and fetal adrenal production of 
the precursor dehydroepiandrosterone-sulfate (DHEA-S). Estrogen increases uterine blood 
flow and increases expression of proteins needed for continued progesterone release as 
well as helps prepare the breasts for lactation (Kallen, 2004). 
 Progesterone  
After week 8, the placenta takes over production of progesterone from the ovary. 
Production is dependent on maternal cholesterol stores and progesterone is essential for 
uterine quiescence (Kallen, 2004). In addition, progesterone modulates the maternal 
immune response to the feto-placental allograft; this hormone also primes the breasts for 
lactation. 
 Human placental lactogen (hPL) 
HPL is structurally district from pituitary growth hormone, 95% sequence homology to 
growth hormone. It is made in syncytium. hPL early in pregnancy modifies metabolic state 
of mother to facilitate energy supply to fetus by stimulating maternal food intake and 
weight gain. 
 Human placental growth hormone (hPGH) 
hPGH is another example of a trophoblast hormone, which allows maternal metabolic 
adaptation to pregnancy. hPGH increases throughout pregnancy and gradually replaces 
maternal pituitary growth hormone. It is the major determinant of maternal insulin 
resistance in pregnancy. Function includes mobilization of maternal glucose for fetus. 
HPGH suggesting effect fetal growth after it has been identified in cord blood (Freemark, 
2006).  
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1.2 Normal parturition 
1.2.1 Definition 
Labour is a process of giving birth to a baby, and is defined as a process of myometrium 
contraction followed by cervical ripening, effacement, dilatation and finally, fetus 
expulsion.  It involves three phases: dilation of the reproductive tract by cervical 
remodelling, rupture of the membranes and then initiation of uterine contraction in a 
rhythmic way.  
 
In humans, parturition includes interaction of immunity, mechanical stretch, hormonal, 
neurological and inflammatory pathways in which the placenta plays a crucial role (Challis 
et al., 2000; Keelan et al., 2003; Petraglia et al., 2010;  MacIntyre et al., 2012).  Placenta 
hormones such as corticotrophin releasing hormone and oxytocin are crucial 
neuroendocrine mediates involved in parturition (MacIntyre et al., 2012). The onset of 
labour is controlled by the interaction between endocrine and immune pathways. 
 
Pregnancy is a unique in that the maternal immune response tolerates the fetal allograft.   
The mother’s immune system could be activated by fetal amniotic fluid derived stretch-
mediated damage-associated molecular patterns (DAMPs) that contribute to labour 
initiation (Petraglia, et al., 2010). Furthermore, Challis, et al. (2000) and Keelan, et al. 
(2003) proposed that there are two phases of the physiological parturition; the first phase is 
started with entry of amniotic components into uterine vessels that could promote 
mechanical stretching.  The second phase is the uterine myometrium contraction.   
 
Increasing evidence suggests that inflammatory markers play an important role in 
physiological parturition. However, many pro-inflammatory mediators such as cytokines 
and prostaglandins are directly implicated in labour (Challis et al., 2000; Keelan et al 
2003; MacIntyre et al., 2012). Previous studies showed that during labour inflammatory 
mediators such as, cytokines are produced by infiltration of activated leucocytes into the 
myometrium, cervix and placenta, and they are involved in initiation of labour. Placenta 
hormones such as CRH and oxytocin are crucial neuroendocrine mediators involved in 
parturition (MacIntyre et al., 2012). The onset of labour is controlled by the interaction 
between endocrine and immune pathways.  
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1.2.2 Parturition and link with oxidative stress  
Oxidative stress occurs when there is an over production of reactive oxygen species 
compared to the intrinsic anti-oxidant defences. It may induce a range of cellular responses 
depending upon the severity of the insult and the compartment in which reactive oxidative 
species are generated (Roberts and Hubel, 2009; Burton and Janiaux, 2011). Labour is also 
associated with placental alterations in several pathways linked to oxidative stress 
(Cindrova-Davies et al., 2007).  Uterine contractions during labour are also associated with 
an intermittent utero-placental perfusion, providing the basis for ischemia-reperfusion type 
injury to the placenta. In relation to this, Doppler ultrasound studies have demonstrated a 
linear inverse relationship between uterine artery resistance and the intensity of the uterine 
contractions during labour (Brar et al., 1988). 
 
 
1.3 Pre-eclampsia 
1.3.1 Definition 
Pre-eclampsia affects about 2 to 3% of all pregnancies but this can be much higher in 
underdeveloped countries. Pre-eclampsia (PE) is an important cause of maternal morbidity 
and mortality worldwide and a leading cause of iatrogenic prematurity and fetal growth 
restriction (Redman and Sargent, 2005). PE has been defined by the International Society 
for the Study of Hypertension in Pregnancy and was defined as a blood pressure of 
>140/90 mm Hg on at least 2 occasions at least 6 hours apart occurring after 20 weeks' 
gestation and accompanied by proteinuria (>300 mg/L in a 24 hour urine collection) with 
no other underlying clinical problems.   
During a healthy pregnancy maternal spiral arteries are remodelled. They become dilated 
and lose their responsiveness to vaso-constrictive stimuli. Blood then enters the intervillous 
space in a non-pulsatile manner and under low pressure (Lyall, 2006). In PE spiral artery 
remodeling is partial or incomplete (Lyall et al., 2013). The resulting high pressure flow 
results in hydrostatic damage to the placental villi. Furthermore perfusion by intermittent 
pulses of fully oxygenated arterial blood is thought to lead to fluctuations in oxygen 
delivery resulting in oxidative stress (Roberts and Hubel, 2009; Burton and Janiaux, 2011). 
The maternal syndrome is, at least in part, due to the maternal response to this damaged 
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placenta (Myatt, 2004). Placental oxidative stress is a feature of PE ((Burton and Janiaux, 
2011, Myatt, 2004) and labor (Cindrova-Davies et al., 2007). 
 
1.3.2 Pre-eclampsia placenta 
The placenta plays a vital role in the pathophysiology of PE. Suboptimal placenta blood 
flow due to incomplete spiral artery remodeling might be the first cause. 
 
1.3.2.1 Failed trophoblast invasion and placental abnormalities in pre-
eclampsia 
Many histological studies have shown that spiral arteries in placenta, decidua and 
myometrium undergo physiological changes in normal pregnancy (Lyall, 2007).  
Normally, these changes result in formation of high capacity low resistance vessels due to 
replacing the endothelium and smooth muscle of the vessels with fibrinoid matrix and 
invasive trophoblast cells. The dilated vessels deliver oxygen and nutrients to the placenta 
and the growing fetus. In PE the trophoblast invasion of spiral arteries in the placental bed 
is restricted and the endovascular trophoblast invasion is also limited to the decidua vessels 
in many cases, and about half of myometrium vessels lose these physiological changes, 
Figure 3. Nevertheless, myometrium vessels may be undergo partial transformation (Lyall, 
2013) that will lead to intermittent contraction resulting in bursts of blood flow and 
ischemic-reperfusion injury to the placenta that is a feature of PE.  Consequently, failure of 
spiral artery remodeling in PE may lead to altered blood flow to the placenta, ensuing 
oxidative stress and release of endothelial damaging factors into maternal circulation.  
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Figure 1-3: Cytotrophoblast cells Invasion of the uterine spiral arteries. Normal pregnancy 
(upper panel): The maternal spiral arteries are invaded by invasive cytotrophoblast cells 
replacing the vascular endothelial layer and the musculoelastic wall, which will form large 
wide, low resistant blood vessels that provide high blood flow to the fetus. In pre-
eclampsia (lower panel): Spiral arteries undergo incomplete remodeling the consequence 
of which is low blood flow to the fetus due to the thick wall and narrow lumen of spiral 
arteries.  Figure adapted from Wang et al. (2009).    
 
1.3.2.2 Placenta pathology and apoptosis 
Decidua arteriolopathy, infarcts, abruption placentas, impaired growth and Tenny-Parker 
changes (increased surface budding of placental syncytium) are obvious changes in the 
placenta in PE (Lyall and Belfort, 2007). These changes become much worse in pre-term 
PE. Tenny-parker changes include protrusions, containing normal nuclei and section of 
syncytial bridges, these changes may be a response to the alteration in oxygen content or 
blood flow to the intervillous space. However, as a part of syncytiotrophoblast turnover, 
there is another form of syncytial knot that removes the old syncytial nuclei. 
Knot like apoptotic shedding may be a way of turnover that involves the apoptotic 
pathway. Moreover, necrotic shedding of the syncytium happens when the aponecrotic 
knots that resemble the apoptotic knots appear with plasma membrane defect, and 
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incomplete apoptotic substrate cleavage replace the apoptotic knots, and this will result in 
shedding membrane bound vesicles to the maternal blood, leading to induce maternal 
inflammatory response. Syncytiotrophoblast micro particles (STBMs) are a feature of PE 
(Southcombe et al., 2011). 
 
1.3.3 Pre-eclampsia and link with oxidative stress  
Pregnancy is a state of oxidative stress.  In part is due to the considerable metabolic 
activity of the placenta and generation of reactive oxygen species. There is irrefutable 
evidence of placental oxidative stress in PE, including increased concentrations of protein 
carbonyls, lipid peroxides, nitrotryosine residues and DNA oxidation (Myatt and Cui, 
2004; Burton and Janiaux, 2011). It is enhanced in PE due to imbalance of pro and anti- 
oxidants in the placenta. There are also signs of endoplasmic reticulum stress in the 
syncytoptrophoblast that has adverse effects on protein synthesis, and oxidative stress in 
mitochondria alters energy metabolism. 
 
 
1.4 PONS 
The paraoxonases (PON) are multifaceted and pleiotropic enzymes encoded by three 
highly conserved genes (PON1, PON2, and PON3) located on chromosome 7q21.3–22.1 
(Primo-Parma et al., 1996). The three members of PON family are 60% identical at the 
amino acid level and approximately 70% similarity at the nucleotide level.The paroxonases 
were named so because the substrate for PON1 is paraoxon which is the active metabolite 
of the organophosphorus insecticide parathion. PON2 and 3 lack this esterase activity 
despite the similar nomenclature. PON1, 2 and 3 are lactones and PON2 has the highest 
activity of the three PONs (Primo-Parma et al., 1996; Draganov and La Du, 2004; Stoltz et 
al., 2007; Teiber et al., 2008; Horke et al., 2010). PON1, 2 and 3 can hydrolyse acyl-
homoserine lactones ((Draganov and La Du, 2004), the latter are molecules which mediate 
bacterial quorum-sensing signals important in the regulation of expression of virulence 
factors and inducing a host inflammatory response (Primo-Parma et al., 1996; Ng et al., 
2001; Stoltz et al., 2007; Horke et al., 2010). They have multifunctional roles and are 
involved in various biochemical pathways. These include protection against oxidative 
damage and lipid peroxidation, modulation of endoplasmic reticulum stress, regulation of 
cell proliferation/apoptosis contribution to innate immunity and detoxification of reactive 
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molecules and bioactivation of drugs (Primo-Parma et al., 1996; Draganov and La Du, 
2004). Phylogenetic analysis has shown that PON1 and PON3 arose from gene duplication 
of the ancestral PON2 gene (Primo-Parma et al., 1996; Draganov and La Du, 2004).  
PON1 and PON3 are circulating proteins associated with high-density lipoproteins (HDL) 
(Deakin et al., 2002). PON2 is expressed in many tissues and is cell associated (Ng et al., 
2001).  PON1 and PON3 proteins are present in plasma and reside in the high-density 
lipoprotein fraction (Ng et al., 2001) and protect against oxidative stress by hydrolyzing 
certain oxidized lipids in lipoproteins, macrophages, and atherosclerotic lesions (Sierksma 
et al., 2007; Jaouad et al., 2006). Paraoxonases are important detoxifying and anti-
oxidative enzymes with roles being described in organophosphate poisoning, diabetes, 
obesity, cardiovascular diseases, and innate immunity (Camps et al., 2009; Shih and Lusis, 
2009). Research in the PON family has increased greatly in the last few years, particularly 
in the cardiovascular field (Martinelli1 et al., 2012). Until the work of this thesis was 
started nothing was known about the role of PON2 and PON3 in the placenta or whether it 
plays a role in labour and PE. As stated above PONs play a role in oxidative stress and 
inflammation, both features of labour and PE. 
 
1.4.1 PON1 
PON1 protein consists of 354 amino acids residues with molecular mass 43-47 kDa 
(Hassett et al., 1991). PON1 is mainly synthesized by the liver and then secreted into 
plasma. The human PON1 mRNA was detected only in liver (Reddy et al., 2001). It 
associates with high-density lipoprotein (HDL) in the circulation (Deakin et al., 2002). 
Small amounts of PON1 were detected in very low-density lipoprotein (VLDL) and 
postprandial chylomicrons (Draganov and La Du, 2004). PON1 hydrolyses several 
substrates; these include organophosphate insecticides and nerve gases, lipid 
hydroperoxides, lactones and thiolactones (Mackness et al., 1991; Jakubowski et al., 2000; 
Draganov and La Du. 2004; Dragomir et al., 2005; Furlong et al., 2008). PON1 is a potent 
anti-atherosclerotic enzyme (Mackness et al., 1993; Watson et al., 1995; Aviram et al 
2000; Jaouad et al., 2006; Sierksma et al., 2007). In human, Kerkeni et al. (2006) 
suggested that the protection role of PON1 against the coronary heart disease is due to 
PON1 ability to hydrolysis of homocysteine thiolactone. Furthermore, Wang et al. (2012) 
showed that low PON1 plasma levels were associated with increased risk of coronary 
arterial disease. However, the antioxidant mechanism is still unclear and it is thought to be 
due to an existence of an enzymatic mechanism rather than PON1 activity of chelating of 
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copper ion or lipid transfer to HDL from LDL (Mackness et al., 1993). In humans with 
atherosclerosis, PON1 immunostaining increases in smooth muscle and endothelial cells 
with disease progression and this is thought to be due to up-regulation by oxidative stress 
(Mackness et al., 1997). In mice, PON levels negatively correlated with atherosclerosis 
(Shih et al., 1998; Ng et al., 2006; Shih et al., 2007). 
 
1.4.2 PON2 
PON2 is an intracellular protein with molecular weight about 44 kDa (Primo-Parma et al., 
1996; Reddy et al., 2001; Ng et al., 2001; Draganov and La Du, 2004). PON2 is more 
widely expressed and is found in a variety of tissues including the liver, lung, heart, 
intestine and stomach (Primo-Parma et al., 1996; Reddy et al., 2001; Ng et al., 2001; 
Draganov and La Du, 2004).  Nothing is known about the function of PON2 in the placenta 
and the only previous report showing expression was from our own group (Alwarfaly et 
al., 2014). Furthermore, Ng et al. (2001) detected that PON2 is also expressed in the 
endothelial cells of arterial wall, smooth muscle and macrophages. PON2 enzyme activity 
is limited to cells however there is the possibility of rapid degradation of PON2 following 
cellular secretion.  In contrast to PON1 and PON3, PON2 is undetectable in HDL or LDL 
(Ng et al., 2001). PON2 has n-terminal similar to PON1 and PON3 but it appears to remain 
intracellular associated with the plasma membrane of cells (Ng et al., 2001). PON2 has 
anti-oxidant properties and protects against LDL oxidation (Ng et al., 2001, Rosenblat et 
al., 2003).  
PON2 expression and activity is up regulated in response to oxidative stress. Ng and co-
workers (2001) demonstrated that PON2 is also able to prevent oxidation of mildly 
oxidized LDL. However how this cellular antioxidant properties of PON2 protects against 
oxidative stress is still unknown and need further investigation (Ng et al., 2004).  
PON2 has several polymorphisms that are associated with number of pathological 
conditions, two common polymorphisms were identified a pair of amino acid substitution 
with alanine or glycine at positions 148 (A148G) and either cysteine or serine at position 
311 (S311C).  A148G polymorphism has been associated with variation of total and LDL 
cholesterol, fasting blood glucose levels and with birth weight (Hegele et al., 1997; Hegele 
et al., 1998; Hegele et al., 1999). S311C polymorphism has been related with coronary 
artery disease, ischemic stroke in patients with type 2 diabetes mellitus and Alzheimer’s 
disease (Sanghera et al., 1998; Wang et al., 2002; Kao et al., 2002; Janka et al., 2002; 
Chen et al., 2003). Furthermore, despite the report of 2 isoforms (found on Western blots) 
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there is no literature reporting where the isoforms have different functions. 
 
1.4.3 PON3 
Among the three PON enzymes, PON3 was the last to be discovered. PON3 is primarily 
synthesised in the liver, and then secreted to the circulation, where it is associated with 
HDL but in much lower levels than PON1. PON3 mRNA is expressed primarily in the 
liver, a low level of PON3 expression can also be found in the kidney (Reddy et al., 2001). 
PON3 has a molecular mass of approximately 40 kDa and also has antioxidant properties. 
Two polymorphisms were identified in the PON3 gene at position 311 and 324.  At 
position 311 is serine to threonine and at position 324 is glycine to aspartic acid (Campo et 
al., 2004). Unlike PON1 and PON2, PON3 has very limited or lack of paraoxonase and 
arylesterase activities, but both enzymes PON1 and PON3 hydrolyse aromatic and long-
chain aliphatic lactones like dihydrocoumarin that can inhibit the oxidation of low density 
lipoprotein (LDL), a function that is believed to slow the initiation and progression of 
atherosclerosis (Reddy et al., 2001). In addition, PON3 hydrolyses some drugs like statin 
lactones (lovastatin and simvastatin) and a diuretic spironolactone (Draganov and La Du, 
2004). Moreover, beside its function in cardiovascular disease PON3 is associated with 
obesity (Shih et al., 2007). Shih et al. (2007) showed that transgenic mice expressing high 
human PON3 had low body weight and low plasma leptin levels compared to their 
littermates. In contrast to PON1 and PON2, PON3 expression does not appear to change in 
response to oxidative stress (Reddy et al., 2001). 
 
 
1.5 Ischemic-reperfusion injury model 
Ischemic reperfusion injury is defined as tissue damage caused as a result of return of 
blood flow after a period of ischemia. During the ischemic period the lack of oxygen and 
nutrient creates an ischemic tissue condition and the length of time that any tissue can 
survive oxygen deprivation varies from organ to organ. Restoration of blood supply leads 
through inflammation and oxidative damage; this is mainly due to free radical activity and 
oxidative stress induction. Ischemic-reperfusion insult is characterized by oxidant 
production, leucocyte–endothelial cell adhesion, platelet–leucocyte aggregation, increased 
microvascular permeability and decreased endothelium-dependent relaxation. Ischemic 
reperfusion injury can lead to multi-organ damage and death (Schofield et al., 2013; Brown 
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et al., 2013; Karatzas et al., 2014). Paraoxonases may be involved in ischemic-reperfusion 
injury, due to their known functions, and therefore are of interest to study in the setting of 
pre-eclampsia. 
 
1.6 Hypothesis 
Nothing is known about the role of PONs in the placenta or whether they play a role in 
labour. However since PON2 and PON3 play a role in oxidative stress and inflammation, 
both features of labour and pre-eclampsia, we hypothesised that placental PON2 and PON3 
expression would increase during labour and pre-eclampsia. We also hypothesised that 
expression would alter at different zones of the placenta. 
 The null hypothesis was there is no different in PONs expression when comparing 
two groups of non-labour to labour and normotensive to pre-eclampsia 
 The true hypothesis was there is a real difference when comparing two groups of 
non-labour to labour and normotensive to pre-eclampsia. 
 
1.7 Aims  
 The first aim of this study was to examine the spatial expression of PON2 and 
PON3 protein and mRNA expression in placentas obtained from women who 
delivered by caesarean section and were not in labour (non-labour group) and 
placentas obtained from women who delivered vaginally following an 
uncomplicated labour (labour group). 
 The second aim was to compare the PON2 and PON3 protein and mRNA 
expression in placentas of non-labour and labour groups at the inner, middle and 
outer sites of the placenta. 
 The third aim was examine the PON2 and PON3 mRNA expression in placenta of 
non-labour pre-eclampsia, labour- pre-eclampsia compared them to normotensive 
non-labour and labour groups.  
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2 Materials and methods  
2.1 Ethical approval 
Ethical approval was performed according to the Declaration of Helsinki. The project was 
approved by the West of Scotland Research Ethics Service- REC 4 (REC reference number 
13/WS/0149, IRAS ID 130896). All information sheets, consent form and ethical approval 
for this study are shown in Appendix 1. Signed patient consent was obtained prior to 
delivery. All the consent was obtained by Dr A. Abdulsid. Placental samples were stored 
within the Institute of Medical Genetics.  
 
2.2 Subjects  
Human term placentas were collected from pregnant women at the Southern General 
Hospital, Glasgow. Placentas were collected from: (1) women who had uncomplicated 
pregnancies and delivered at term either spontaneous vaginally (labour group) or by 
elective caesarean section (non-labour group). The labour group was all spontaneous 
labour and a tight group (labour time minimum 3 hours and maximum 8 hours). Caesarean 
sections were performed for obstetric reasons such as breach presentation, previous 
caesarean section or maternal request. Patient consent was obtained prior to delivery. The 
groups studied had no underlying maternal conditions such as hypertension, PE, diabetes, 
gestational diabetes or any other medical disorders. There was no fetal pathology such as 
FGR.  (2) Women who had pregnancies complicated by PE (non-labour group or labour 
group). (3) Women who pregnancies complicated by FGR. PE was defined as pregnancy-
induced hypertension (blood pressure ≥140/90 mm Hg) and proteinuria (≥300 mg/24 h) in 
women who were normotensive before pregnancy and had no other underlying clinical 
problems, such as renal disease (Brown et al., 2001). The patients’ details are shown 
in Table 2-1 below.  
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Table 2-1: Patient clinical details. NLG (non-labour group); LG (Labour group); NLG-PE 
(non-labour-PE); LG-PE (labour-PE); EMC/S (emergency caesarean section); ELC/S 
(elective caesarean section); SVD (spontaneous vaginal delivery); BMI (body mass index); 
PG (prim gravida); G refers to the number of pregnancies the woman has had and P refers 
to the number of live children from these pregnancies. PO+2=2 miscarriages 
 
Sample Age 
years 
Parity  Smoker Gestation 
(weeks/ 
days) 
Birth 
weight 
(g) 
Placenta 
weight 
(g) 
Mode of 
delivery 
BMI 
NLG  22 G3P2 NO 38 +4  3840 680 ELC/S 37 
NLG 34 G2P1 NO 41+3 3100 450 ELC/S 30.6 
NLG 26 G2P1 YES 39  2860 683 ELC/S 23 
NLG 22 PG YES 39+2 3050 465 ELC/S 21 
NLG 34 G3P2 NO 39+1 3555 685 ELC/S 32.4 
NLG 32 G2P1 NO 39  4255 605 ELC/S 27 
LG 27 PG NO 40+2 4192 585 SVD 24 
LG 28 PG NO 40+4 3646 595 SVD 28 
LG 22 PG NO 41+3 3940 700 EMC/S 34 
LG 25 PG NO 41+3 3310 486 SVD 24 
LG 28 G3P2 NO 37+6 3354 636 SVD 26 
LG 25 G4P3 NO 41+1 3870 535 SV 33.9 
NLG-PE 34 G3P2 NO 39 3490 592 ELC/S 27 
NLG-PE 33 PG NO 36+6 2800 450 ELC/S 39 
NLG-PE 28 G2P0 YES 36+3 4525 1309 ELC/S 57.3 
NLG-PE 38 G2P1 NO 39  3736 695 E/CLS 47.2 
NLG-PE 29 G2P1 NO 37 +3 3210 675 ELC/S 32.2 
LG-PE 42 G6P4 NO 36+6 2248 449 EMC/S 29 
LG-PE 32 PG NO 38+1 2812 521 SVD 23 
LG-PE 30 PG NO 28+5 1230 265 EMC/S 29.7 
LG-PE 32 PG NO 38+3 2990 420 EMC/S 21.9 
LG-PE 28 PG NO 40+6 3530 692 SVD 26.7 
LG-PE 17 PG NO 29+2 1260 317 EMC/S 23 
LG-PE 35 PO+2 YES 35+6 2210 780 SVD 29.2 
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2.3 Patient clinical data analysis  
The combined analysis for all the patients shown in Table 2-1 is shown in Table 2-2.  
There was no significant difference in maternal age, placental weight and birth weight 
between all groups except gestational age at delivery was reduced in the LG-PE compared 
to the LG-C. Smoking did not affect the results. Comparison of groups was performed with 
the one way ANOVA statistic test. Comparison of two groups was performed with the 
Mann-Whitney test. 
 
Table 2-2: Shows the demographics of patients used for placenta collection 
 
 
2.4 Sampling methods 
Placentas were obtained directly after delivery, washed in water and the amnion was 
removed. The placenta was divided into zones. For each control patient placental samples 
(~1 cm
3
) were obtained from three zones by taking measurements from the cord insertion 
point: 0–2 cm (inner zone), 2–4 cm (middle zone) and 4–6 cm (outer zone) of the placenta 
(Figure 2-1).  Within each zone four separate samples were obtained representing the four 
CATEGORY NLG-C 
(n=6) 
LG-C (n=6) NLG-PE 
(n=5) 
LG-PE 
(n=7) 
p-value 
Maternal age 28.33±5.7 26±2.28 32.4±4.03 30.57±6.88 p=0.2 
Placenta weight 594.7±110.5 589.5±75.0 662.2±164.12 591.7±161.4 p=0.7 
Birth weight 3443±537 3719±347 3552±645.54 2959±567 p=0.09 
No. Prim gravida 1 4 1 6  
Gestation age at 
delivery 
39.3±1.0 40.31±1.4 37.64±1.29 38.55±2.024 NLG v LG 
(p=0.2) 
NLG  v 
NLG-PE 
(p=0.05) 
LG v LG-PE 
(p=0.02) 
No. smokers 2 0 1 1  
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quadrants as previously described (Abdulsid et al., 2013, Abdulsid et al., 2014, Abdulsid 
and Lyall, 2013). Placentas had a central cord insertion. Samples were rinsed and 
immediately flash frozen in liquid nitrogen. 
 
 
 
Figure 2-1: picture shows areas where samples were taken in each individual placenta. 
 
 
2.5 Collection and processing of the placenta tissue 
2.5.1 Tissue collected for protein and molecular analysis  
All equipment used for the tissue collection was sterile and the appropriate number of 
cryostat containers was put in dry ice to ensure they were cold. Tissue samples were 
collected and washed three times in phosphate buffered saline (PBS) until the blood was 
washed away, then immediately flash frozen in liquid nitrogen. Snap frozen tissue was 
then brought to the lab on dry ice and kept at -80 C until processed.  
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2.6 RNA extraction from placenta tissue 
2.6.1 RNA extraction  
RNA was extracted from placenta samples by using the RNeasy Midi Kit (Qiagen cat. no. 
75142) Figure 2-2. Three steps were followed as per the manufacturer’s instructions.  
 Preparation of working solution: A working solution was made prior to use 
according to the Qiagen kit recommendations: β-Mercaptoethanol (β-ME) was 
added to RLT buffer (10µl β-ME per 1ml of RLT buffer). Buffer RPE was 
supplied as a concentrate; 11ml was added to 44ml of ethanol to obtain 55ml of 
Buffer RPE. 
 Homogenization of tissue: The frozen tissue sample was removed from -80° C 
storage and placed in a pre-weighted plate to determine the correct amount of 
starting material (maximum 250 mg of tissue). The suitable amount of placenta 
tissue was disrupted in 4 ml RLT buffer (buffer provided with kit). The tissue was 
then homogenised using a (Polytron PT1600E, Lucerne) Rotor-stator homogeniser 
(Kinematica) at maximal setting speed for 3x20 seconds until uniform 
homogeneity. After that, the homogenising lysate from each sample was spun in 
the centrifuge (4000g, 25°C for 10 minutes). The supernatant was then transferred 
carefully to a new 15ml Falcon tube (Sigma-Aldrich, cat.no.Z617849).  Then 
4.0ml of ethanol (70%) was added to the supernatant. The tube was immediately 
shaken vigorously until the solution was clear. 
 Extraction of total RNA: an appropriate number of RNasey® Midi kit spin 
columns already contained within the 15 ml collection tubes (provided in kit) were 
retrieved and 4 ml of mixed supernatant (ethanol and supernatant) was added to 
the column which was then spun in centrifuge (4000g, 25°C for 5 minutes). The 
flow-through was discarded. This step was repeated twice until all supernatant had 
gone. Next the column was washed three times as follows: 4.0ml of RW1 buffer 
(provided with kit) was then added to the RNeasy column which was then spun in 
the centrifuge (4000g, 25°C, for 5 minutes); the flow-through was discarded again. 
RPE buffer (2.5 ml) (provided with the kit) was then added to each RNeasy 
column and spun down in the centrifuge (4000g, 25°C for 2 minutes). Another 2.5 
ml of RPE buffer was added to each column and spun again in the centrifuge 
(4000g, 25°C for 5 minutes) in order to dry the RNeasy silica-gel membrane. For 
RNA elution, the RNeasy column was transferred to a new 15 ml collection tube 
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(provided with the kit). Of RNase-free water (250 µl) was added into the RNeasy 
silica-gel membrane and allowed to stand for 1 minute. After that the columns 
were spun down in the dcentrifuge (4000g, 25°C for 3 minutes). This step was 
then repeated with same volume of RNase-free water. 
 
 
Figure 2-2: RNeasy Midi Kit (Qiagen .cat.no. 75142). 
 
 
2.6.2 Quantification of RNA  
The quantity of total RNA concentration (ng/µl) present in the sample was calculated by 
using a spectrophotometer NanoDrop 1000™ (Thermo Scientific, USA). The Nanodrop 
was first blanked with 1.5µl of RNAase-free water (same elution material) and the 
obtained value in the blank state served as a comparison value. After that the RNA samples 
were measured one by one. The reading at 260 nm gives an estimation of the amount of 
RNA. The ratio of absorbance at 260/280 reading indicates the RNA purity of the sample; 
a ratio close to 2 indicates optimal purity. The final measurements were in ng/µl. (Figure 2-
3 and 2-4). 
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Figure 2-3: Example of transcript from Nanodrop reading in ng/µl (arrow). The ratio of 
absorbance at 260 nm and 280 nm (260/280) (Arrow) is given an indication of RNA purity. 
 
 
Figure 2-4: RNA concentration of placenta sample number 10p6 in ng/µl (390.1) 
 
 
2.7 Converting mRNA into cDNA (Reverse transcription) 
RNA cannot serve as temple for PCR so a reverse transcription step is required.  The 
protocol for the reverse transcription was performed using the Quanti-Tech Kit (Qiagen, 
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cat. no 205310) Figure 2-5 and Go Script™ reverse transcriptase (Promega, cat. no. 
A5003). As a result of optimization process in our lab, the quality of cDNA obtained using 
GoScript™ reverse transcriptase reaction was better than reverse transcriptase of the 
Qiagen kit. 
 
 
Figure 2-5:  Quanti-Tech Kit (Qiagen, cat.no 205310) 
 
 
Reverse transcription including two steps as following:  
2.7.1 Genomic DNA elimination reaction: 
mRNA and Quanti-Tect® kit were removed from -80 C and -20 C storages respectively 
and kept on wet ice at all times. Then amount of RNA required for 100 ng was calculated 
based on their original concentration. 
 
For each DNA elimination reaction in each PCR tubes the following was made: 
 Wipe-out buffer- 2μl 
 RNA (100ng)- X (volume depends on each sample conc) all, and RNase free water 
Y all (total 12 µl) 
 Total reaction volume- 14μl 
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Once the reaction was set up, the tubes were put through the gOUT program, using a 
thermal cycler (DNA Engine®, Bio-Rad). 
 3 minute at 42°C 
 
 
2.7.2   Reverse transcript (RT) reaction in each PCR tube: 
The master mix was made up for the reverse transcription reaction as follows: 
 GoScript Reverse transcriptase - 1μl 
  RT Buffer -4μl 
 RT primer Mix-1μl 
Once the reaction was complete, the PCR tubes were removed and the master mix was 
made up. A volume of 6µl of master mix was then added to each tubes containing 14µl of 
RNA that had gone through the gnu wipe-out program.  
 Total reaction volume 20 µl 
PCR tubes were put again into the thermal cycler using the RT4 program, 
 30 minutes at 42 °C 
  5 minutes at 95 °C (enzyme deactivation) 
Once the reaction was completed, cDNA was stored in -20 C. 
 
 
2.8 Testing cDNA quality 
The cDNA quality was checked using the human cDNAOK!® kit (Microzone, cat. no. 
2HCDOK-150). The human cDNAOK mix and mega Mix-Gold are supplied from 
Microzone and it was not known for the customers.  Interpretation of results as following: 
expected fragment size: 125 bp, 250, 375, 500 and 650 bp. If all 5 fragments are observed 
the cDNA is likely to be okay.  The 500 bp (arrow) fragment is derived from an internal 
control and should always be present (even in negative control), if not, PCR has failed and 
needs repeating. However, if less than 5 fragments are observed then the cDNA is likely to 
not be okay.   
Methods: In each tube was added 
 Human cDNAOK!® Kit mix  7.5µl 
 Master mix Gold                   12.5µl 
 H2O                                           4µl 
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 cDNA                                        1µl 
 Total volume of reaction         25µl 
Once the reaction was complete the PCR tubes were put into the thermal cycler program 
(cDNAOK) 
o 95°C for 30 seconds 
o Then for 35 cycles:  
 95°C for 30 seconds 
 59°C for 20 seconds 
 72°C for 45 seconds 
Once completed, the PCR products were separated on a 2% agarose gel at 100 volts 
constant voltage Figure 2-6.  
 
 
 
Figure 2-6: PCR multiplex using the Human cDNAOKᴉ® Kit (Microzone, cat. no. 
2HCDOK-150). cDNA was made using the Quantitect® kit and GoScript™ reverse 
transcriptase. Products were separated on 2% agarose gels using a 100 bp ladder (Sigma-
Aldrich, cat.  no.P1473). 
  
 
2.9 Quantitative real time polymerase chain reaction 
(qRT-PCR) 
All equipment and bench space were sterilized with 70% ethanol before starting the 
experiment. cDNA was removed from -20°C storage and allowed to thaw on wet ice. The 
TaqMan Master Mix (Applied Biosystem, cat. no 4369514) was used to investigate mRNA 
levels of different genes by using the StepOnePlus® qPCR machine (Applied Biosystems). 
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TaqMan gene assays were used according to manufacture guidelines. -actin was used as 
an endogenous control. Placenta cDNA (primer design) (Figure 2-7) was used as a 
reference sample. RNA free water was used as negative control (Figure 2-7). Samples and 
reference sample were diluted 1/5 (1µl cDNA+ 4µl dH2O). The master-mix was made for 
every primer used within a single experiment.  
Typical master-mix and cDNA per would be as follows: 
 Master mix --- 10µl 
 dH2O-----        4µl 
 diluted cDNA- 5µl 
 TaqMan Gene Expression Assay 1µl  
 Total volume--- 20µl  
PON2 TaqMan Gene Expression Assay (Applied Biosystems, cat.no: Hs00165563_m1), 
PON3 TaqMan Gene Expression Assay (Applied Biosystems, cat. no: Hs01023629_m1 
and cat no: Hs01023630_m1).  
 
The experiment was set up in microamp® fast optical 96 well plates (Applied Biosystems, 
cat. no. 4346906). A plastic cover was added after the plate was set up. The plate was 
mixed and then spun in a centrifuge (4860g for 90 seconds) in order to remove any bubbles 
after which the plate was put in a qPCR StepOnePlus machine and the run was performed 
according to following qPCR programme: 
Holding stage: 
 50 C for 2 minutes 
 95°C for 10 minutes 
Cycling stage X50: 
 95 C for 0.15 minutes 
 60 C for 1 minute 
Once the programme was completed, the plate was kept in the fridge. 
Different gene expressions were compared using the comparative Cᵗ methods of Applied 
Biosystem software® v2.1 in order to obtain a relative quantification (RQ) of gene 
expression. Example of PON2 and PON3 amplification plot is shown in Figure 2-8. 
TaqMan® Assays are primer and probe sets based on 5’ nuclease chemistry using 
TaqMan® MGB (minor groove binder) probes, the most quantitative gene expression 
technology available by Applied Biosystems. 
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Figure 2-7: Left panel: The negative control (RNA free water) showed no expression, Right 
panel: Placenta cDNA (positive control) showed clear expression from cycle number 16. 
 
 
 
Figure 2-8: Left panel: PON2 gene expression the average Ct. Value (arrow) around cycle. 
No. 30. Right panel: PON3 gene expression the amplification started after 35 cycles the 
average Ct. Value (arrow) around cycle. No. 38. 
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2.10 Placental tissue preparation for protein expression 
analysis 
2.10.1 Homogenisation of placenta tissue 
Homogenising buffer contained: 25 mM Tris buffer (25 mM Tris 75 mM NaCl with the pH 
adjusted to 7.6), 1mM Ethylenediaminetetraacetic acid (EDTA), and 250 mM sucrose. The 
buffer was stored at 4C. 12.5µl/ml mammalian cell protease inhibitor cocktail (Sigma 
Aldrich cat. no. P8340-5ml) was added immediately prior to use on the day of the 
experiment. Relevant tissue samples were retrieved from –80 C storage. Tissue samples 
were ground down to a fine powder in liquid nitrogen using a pestle and mortar. An 
appropriate volume of homogenising buffer supplemented with protease inhibitor cocktail 
was added to the fine tissue powder. Samples were homogenized using a rotor-stator 
homogeniser (polytron® PT 1600E, Lucerne, Kinematica) at speed 20 for each sample, 
with 5x10 second intervals and 1 minute cool down on wet ice in between. The tissue 
homogenate was spun in a centrifuge (4860g for 10 minutes at 4 C) to remove debris. The 
supernatant, containing the total protein (both particular and cytosolic fraction), was 
extracted, allocated and stored at -80 C.  
For each tissue sample  
 The sample was ground down and kept cold.  Bijous was labelled with the relevant 
sample name were weighed in grams without the lid on, and then balanced to zero. 
The relevant sample was retrieved to be homogenised and put into its relevant bijou 
determine the weight of the tissue. Then 3 times the amount of buffer (ml) for the 
weight of tissue sample (grams) was added. 
 Tissue homogeniser: Homogenisation was switched on by using speed 20 for each 
sample x5, for 10 second each with 1 minute cooling interval. The tissue sample 
was left in the bijou on ice at 4 C. 
 Centrifugation: 15 ml labelled conical tube containing lysate at 4860g for 10 min at 
4 C. The supernatant is systolic protein and the pellet is “junk” protein. New 1.5 ml 
Eppendorf’s was retrieved and the supernatant (total/cytosolic protein) was pipetted 
off into labelled Eppendorfs. The pellet (junk protein) was discarded. 
 Tissue homogeniser: Homogenisation was switched on by using speed 20 for each 
sample x5, for 10 second each with 1 minute cooling interval. The tissue sample 
was left in the bijou on ice at 4 °C. 
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 Centrifugation: 15 ml labelled conical tube containing lysate was spun using 4860g 
for 10 min at 4 °C. Supernatant will be systolic protein and the pellet will be junk 
protein. New 1.5 ml Eppendorfs was retrieved and the supernatant (total/cytosolic 
protein) was pipetted, ensuring that the Eppendorfs were labelled, and that the 
pellet (junk protein) was discarded into the bin. 
 
 
2.10.2 Protein estimation using Bradford assay 
The method described by (Bradford, 1976) was used to quantify protein concentration. 
Sample protein concentration can be measured by mixing protein solutions with the acidic 
brown comassie-dye reagent (Bradford reagent), which alters it to a bluish colour. 
Changing of the colour alters the absorbance maximum of the protein from 465 nm to 595 
nm. The colour response of the sample protein is compared to that of standard samples 
which is usually bovine serum albumin (BSA). The stock standard solution (STD) of 
bovine serum albumin (BSA) (1 mg per ml) was used to create the standard curve as 
shown in Table 2-3: 
 
Table 2-3: Concentration of STD 
STD concentration 
(µg/ml) 
Vol. stock STD (µl) Vol. of d H2O (µl) 
0 N/A 50 
200 10 40 
400 20 30 
600 30 20 
800  40 10 
1000 50 N/A 
 
 
Procedure  
Samples were diluted by 1/40 (39 µl of dH2O and 1 µl of homogenate). Measurements of 
different concentrations were prepared using a BioPhotometer® (Eppendorf). Standards 
were used to create the standard curve against which the sample’s concentration was 
measured. Example of standards curve is shown in Figure 2-9. For a Western blot 50 µg 
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was required for loading. The calculation (the reading value /1000 (convert µg to mg 
(mg/ml) x40 (dilution factor) 1000 to convert µg to mg (mg/ml), divided by the dilation 
factor of 40 the dilution factor. For 50 µg the appropriate volume could then be calculated 
for loading. 
 
Protocol summary:  
The stock standard solution: 1 mg per ml of BSA, 20 mg in 20 ml H2O. 6x 0.5 ml 
Eppendorf tubes were labelled for making up the different concentration of standard 
solutions as shown in Table 3.   
Sample dilution: Relevant samples were retrieved from freezer then Eppendorfs tubes were 
labelled. Samples were diluted by 1/40 (39 µl of dH2O and 1 µl of homogenate). For 
standards assay preparation: New 1.5 ml Eppendorf tubes were labelled for each STD 
solution and 10 µl of each STD solution was added to their relevant tubes. For sample 
assay preparation: 2 new 1.5ml Eppendorfs tubes were labelled for each sample, 10 µl of 
the diluted sample was added into each tube. Bradford’s reagent was retrieved from fridge 
and 200 µl was added to each tube which was containing 10 µl of standards or sample. All 
of them was vortex and was allowed to stand for 30 minutes. 180 µl of each 
sample/standard solution mixed with the Bradford’s reagent was added to their relevant 
curvette, and then analyse using a biophotometer was carried out. Standard curve was 
created using standards and against this curve the sample concentrations was measured as 
shown in Figure 3. For a Western blot 50 µg was required for sample loading, calculation 
was carried out as following the reading value /1000x40 (1000 to convert µg to mg) 
mg/ml. (40 the dilution factor).  
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Figure 2-9: Picture represents one example of standard curve reading  
 
 
2.10.3 Western blot 
Sodium deodecyl sulphate (SDS) is used to denature and reduce the protein resulting in 
loss of the three dimensional structure of the protein. Migration of proteins by SDS 
polyacrylamide gel electrophoresis (SDS-PAGE) is determined by negative charge of the 
SDS. Separation of proteins is determined by the size of the pores of the gel thus a 10% 
resolving gel and 4% stacking gel was used.  
 
2.10.3.1 Samples preparation and gel electrophoresis  
Samples (including control) were mixed 1:1 with loading buffer and boiled on a heat block 
for 5 minutes at 95 C before loading. Each well was loaded with 50µl of protein. 20µl of 
pre-stained SDS-PAGE Standards (Low range, BIO-RAD, cat. no. 161-0305) was loaded 
to allow the size of proteins to be identified. 50 µl of positive control (placenta 
homogenate) was loaded into the gel and used as a reference sample. Samples were 
separated using the Protean II® xi Cell System (Bio-Rad Laboratories, Hemelhempstead, 
UK) at 300 V, 27 Amp for the first hour then turned up to 30 Amp, total time period of 
about 5 hours Figure 2-10. Summary of western blot protocol is as follows: 
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Figure 2-10: PROTEAN II xi systems by BIO-Rad Laboratories 
 
 
2.10.3.2 Reagents for gel preparation: 
Buffer A’ for resolving gel: 
 1 litre of dH2O, 181.65 g of Tris, and 40 ml of 10% SDS was added. Allowed to 
dissolve. pH to 8.8 
Buffer B’ for stacking gel: 
1 litre of dH2O, 60.55g of Tris, and 40 ml of 10% SDS solution was added. Allowed to 
dissolve.  pH 6.8  
Running buffer 
 3.8 L of dH2O, 60.4 g of Tris, 288 glycine, 200 ml of 10% SDS solution. pH to 8.3 
Running buffer diluted: 
 0.5 L running buffer (5x),  2 L of dH2O. 
Resolving and stacking gels:  see Table 2-4. 
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     Table 2-4: Resolving (left column) and stacking gels (right column) composition  
 
10% AMPS solution (AMPS-ammonium per sulphate) 
 1 ml of dH2O, 0.1 g of ammonium persulfate (Sigma-Aldrich, cat. No. A3678-
100G). 
 TEMED: N,N,N,N tetramethylethylenediamine (Sigma-Aldrich, cat.no.T9281-
100ML). 
Sample preparation  
 Samples (and control) were put on heat block for 5 minute at temp 95C. 
 The central reservoir of a cooling tank was filled with running buffer to check for 
leaks (PROTEAN II xi system by Bio-Rad Laboratories, UK). See Figure 13. 
 20 µl of molecular ladder (BIO-RAD, 161-0305) was loaded onto one well of the 
gel, and once samples were heated, 50 µl of each was added to their relevant wells 
in the gel. 
 Gels were run at 300 V, 27 Amp for first hour then up to 30 Amp for a  total time 
period of about 5 hours until the dye front had reached the bottom. 
 
Reagent  Resolving gel (2 gels) 
        (10%) 
Stacking gel (2 gels) 
      (4%) 
 Volume Volume 
30% acrylamide 24 ml  2.7 ml  
50% glycerol 4.8 ml N/A 
Buffer A 18 ml N/A 
Buffer B N/A 5 ml 
Distilled water  24.8 ml 12.2 ml 
10% AMPS 360 µl  100 µl 
TEMED 36 µl 20 µl 
Total  36x2 ml 20 ml 
  50 
 
2.10.3.3 Transfer of proteins to Nitrocellulose (semi-dry transfer): 
Proteins were transferred to Whatman Protran® nitrocellulose transfer membranes (Sigma-
Aldrich, cat. no. Z61360). Two blotting papers and the nitrocellulose paper were kept in 
transfer buffer for 20 minutes. The transfer was undertaken using the Trans-Blot SD Semi-
Dry® Electrophoretic Transfer Cell (Bio-Rad, cat. no. 170-3940) with paper for blotting in 
the following order: 1) first blotting paper, 2) then the nitrocellulose paper, 3) then the gel 
on top of the nitrocellulose, 4) then the second piece of blotting paper. The transfer was 
performed at 22 Volts for 30 minutes, the current (mAmp) used depends on the dimensions 
of the gel (current= gel area x2.5) Figure 2-11. Once transfer was completed the 
nitrocellulose was stained with Ponceau S solution to determine that protein had been 
transferred. Once done, the nitrocellulose was destained in 0.1% NaOH solution Figure 2-
11. 
 
 
Figure 2-11: Upper panel: Semi-dry transfer cell and lower panel: Illumination of 
membrane by Ponceau S solution to ensure transfer. 
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Protocol summary 
Reagents: Transfer buffer: 800 ml H2O, 3 g Tris, 14.4 g glycine and 200 ml 
methanol. Once the gels have run the stacker gel and bottom of the resolving gel 
were removed and both were discard. Remaining gel was measured and put into a 
box containing the 2 pieces of blotting paper. Nitrocellulose paper was cut (20 cm x 
15 cm) and was put into the box containing transfer buffer for 20 minutes. Semi dry 
transfer cell (BIO RAD, 170-3940) was retrieve and then 20 minutes later one piece 
of blotting paper was placed and then the nitrocellulose, gel was placed on top of 
the nitrocellouse, and then the second piece of blotting paper was placed on the top. 
Transfer at 22 V for 30 minutes was done, the current (mA) used depends on the 
dimensions of the gel (current= gel area x2.5).Visualise the nitrocellulose was 
carried out using Ponceau S solution (Figure 14) in order to check protein presence. 
Once done, de-stain nitrocellulose in 0.1% NaOH solution was carried out. 
 
2.10.3.4 Immuno-detection of proteins (Immune-blotting) 
Reagent: TBSTB (1 Litre): 1L of dH2O, 2.4g Tris, 3ml of concentrated HCL (pH 7.5), 
29.2g NaCL, 4ml   Tween 20 and  2.5g BSA. Summary of protocols for immune detection 
of protein is in Tables 5, 6, and 7). 
Membranes were blocked in 5% normal donkey serum (Serotec, cat. no CO6SBZ) for 
PON3 or 5% normal goat serum (Sigma-Aldrich, cat.G9023) for PON2 Table 2-5. 
 
Table 2-5: Blocking protocol for PON2 and PON3 
 
Primary antibodies were pre-absorbed for 30 minutes in 5% normal human serum (Sera 
Laboratories International, cat.no. S-123-H) in TBSTB at room temperature during the 
blocking stage. Membranes were incubated with appropriate primary antibodies solution, 
for example: PON2 (Santa Cruz cat.no. sc-373981), PON3 (Santa Cruz, cat.no. sc-21152) 
Table 2-6. 
 
PON2 blocker PON3 blocker 
5% normal goat serum in TBSTB for 1 hour 
at room temperature. 
5% normal donkey serum in TBSTB for 1 
hour at room temperature. 
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Table 2-6: Primary antibodies protocol for PON2 and PON3 
PON2 primary antibody PON3 primary antibody 
5% Normal Human Serum (NHS) in 
TBSTB with Mouse monoclonal anti human 
PON2 primary antibody (Santa Cruz cat.no. 
sc-373981) (1:200) for 1 hour at room 
temperature 
5% Normal Human Serum (NHS) in 
TBSTB with Goat polyclonal anti human 
PON3 primary antibody (Santa Cruz, cat.no. 
sc-21152) (1:200) for 1 hour at room 
temperature.                                          
 
Membranes were rinsed and washed in TBSTB (3X5 minutes), and then incubated with 
appropriate horseradish peroxidase conjugated secondary antibodies for PON2 (Goat anti-
mouse IgG-HRP, Santa Cruz, cat.no. sc-2005), for PON3 (Donkey anti-goat IgG-HRP, 
Santa Cruz, cat.no. sc-2020) for 1 hour at room temperature Table 2-7. 
 
Table 2-7:  Secondary antibodies protocol for PON2 and PON3 
 
The membranes were washed in TBSTB for 2x5 minutes and in water for 1x5 minutes 
after secondary antibody incubation. 
 
 
2.10.3.5 Detection  
Immunologically reactive proteins were visualised using the Amersham ECL® Western 
Blot detection system (Amersham Pharmacia Biotech, GE healthcare, cat. No RPN2106 
Figure 2-12. Membranes were placed in a film cassette and films were exposed in a dark 
room for an appropriate period of time (e.g. 1 min, 30 sec then 10 sec) to obtain the 
correctly exposed bands suitable for scanning. Exposures were selected that were not 
saturated. Bands on films were scanned using a Bio-Rad GS-700® imaging densitometer. 
The reading for placental control sample (same one used in all experiments) was used as 
internal control and the density of the other bands was expressed relative to it. 
 
PON2 secondary antibody  PON3 secondary antibody 
Goat  anti-mouse secondary antibody 
1:2000  For 1   hour at room temperature                                     
 
Donkey anti-goat secondary antibody 
1:2000 For 1 hour at room temperature                                     
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Figure 2-12:  Detecting using ECL solution for 1minute 
 
2.10.4 Loading controls 
2.10.4.1 β Actin  
Actin β was used as loading control to ensure the equal loading among samples Figures    
3-12 and 3-15. β Actin protocol according to the following Table 2-8: 
 
Table 2-8: Actin β protocol  
Blocker Primary antibody Secondary antibody 
5% normal donkey 
serum in TBSTB for one 
hour at room 
temperature. 
Anti-actin Rabbit polyclonal 
antibody (ab8227) in TBSTB 
and pre-absorbed in 5% 
normal human serum 1:2000 
for one hour at room 
temperature. 
HRP-donkey anti rabbit 
secondary antibody (ab7083) 
in TBSTB 1:3000 for one 
hour at room temperature. 
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2.10.4.2 Ponceau S Solution  
Ponceau S solution was used to ensure the protein transfer and to show equal loading 
among samples Figure 2-13. 
 
Figure 2-13:  Example of two membranes illuminated with Ponceau S solution, which used 
as a loading control. 
 
 
2.11 Hypoxia-normoxia (model of ischemic-reperfusion   
injury) tissue culture 
The reperfusion experiments was undertaken to investigate the effect of exposing placenta 
tissue to 2% (hypoxia) for one hour followed by exposure to 8% (normoxia) O2 for 4 time 
points (2, 6, 12 and 22 hours).  The oxygen concentration in placenta tissue is 8%. This 
tissue experiment was done to recreate the type of reperfusion of placenta that occurs in 
labour and PE when vessels contract and relax and to examine this effect on expression of 
selected genes. The experiments carry out as follows Table 2-9: 
Table 2-9: Preparation steps for reperfusion experiment 
Preparation (day before experiment) 
 The internal surface of incubators and cell culture chamber were cleaned using 70% 
ethanol the day before experiment. 
 The incubators were set up 24 hours before tissue collection:  
    NuAir incubator 1 at 2% O2 (hypoxia) 
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    NuAir incubator 2 at 8% O2 (normoxia) 
 Six 24 well culture plates and three T5 culture flasks were retrieved. 
 Every 20 ml of M199 media was supplemented with 1ml of FBS (fetal bovine 
serum) and 0.2ml Ab/Am (antibiotics/ antimycotics). 
Medium199 (with Earle’s salts, L-glutamine and sodium bicarbonate, liquid, sterile-
filtered, cell culture tested) (Sigma, cat. no. M4530-100ML). 
5% fetal bovine serum (heat inactivated) (Sigma-Aldrich, cat. no. F9665) 
1% antibiotic antimycotic solution (Sigma-Aldrich, cat. no. A5955) 
 10 ml of supplemented media was added to the labelled culture flasks and 1 ml of 
supplemented media was added to 6 wells of six 24 well culture plates. 
  Plates (24 well culture plates) were put into each incubator that was set to the 
desired oxygen concentration for 24 hour prior to tissue collection so that that 
desired oxygen concentration was reached. 
 Three T5 culture flasks with 10 ml of supplemented media were put in 8% O2 
incubator that closes to placenta oxygen concentration for 24 hours before tissue 
collection. 
 
 
 
The experiment: 
 Step one: Normal placenta tissue was collected. The T5 culture flasks were 
removed from the incubator. For base line control three piece of placenta tissue 
(inner, middle and outer areas) were removed and immediately flash snap in liquid 
nitrogen. The rest of each piece of tissue collected was cut into three parts and put 
into 8% O2. 
 
In culture lab: 
 Step two: The tissue was taken to the laboratory at Yorkhill Hospital and the 
second reference point of placenta tissue was taken. 
 Step three: The placenta tissue was removed quickly and cut up into equal sized 
pieces. The 24 wells culture plates were removed from both incubators and 
placenta tissues were distributed into an equal number of wells in each plate, after 
which the tissue culture plates were retained back to their relevant incubators.  
 Step four: The hypoxia exposure time for all placental pieces (inner, middle and 
outer) was 1 hour at 2% O2, after which the tissues plates were removed, placed in 
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pre-equilibrated 8% O2 medium and transferred to the 8% O2 incubator. The 
experimental times were after 2, 6, and 12 and 22 hours after the 2% O2 plates were 
placed in 8% O2 incubator. Control samples underwent the same process except the 
first hour was in 8% O2 medium rather than 2% O2. 
 Step five:  at each time point  (2, 6, 12, 22 hours) the relevant tissue plate were 
taken from the incubator and tissue at inner, middle and outer areas were snap 
frozen in liquid nitrogen. 1ml of tissue culture media were taken in each point and 
stored for cytokine analysis should time allow in the future. 
 
RNA were then extracted from the frozen tissue and RNA was later reverse transcribed 
into cDNA and used for subsequent investigation of PON2 and PON3 mRNA analysis as 
described earlier. 
Tissue protein was obtained using the homogenisation process described earlier and PON2 
and PON3 protein expression were investigated using the Western blot method.  
 
 
2.12 Statistical analysis:  
Statistical analysis was performed using Graph Pad prism 5 using analysis of variance for 
non-parametric data (Friedman test) for 3 groups. Comparison of two groups was 
performed by the Mann Whitney test. Graphs show box and whiskers plots. The hypoxia-
normoxia experiment statistical analysis was performed using Minitab 17, using two ways 
ANOVA to measure the response compared to two factors (hypoxia and time). Graphs 
show interaction plots. 
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3  Results 
3.1 PON2 expression in the labour group 
Experiment 1: This experiment was designed to test if there was a spatial difference in 
expression of PON2 within individual placentas obtained from women who were not in 
labour. Two main bands were detected in all placenta samples, one at 62 kDa and one at 43 
kDa. These are named as isoform 1 62kDa and isoform 43 kDa throughout. Examples of 
Western blots showing PON2 (isoform 1, 62 kDa) expression for 3 different placentas (all 
non-labour) are shown in Figure 3-1 (blots A-C). Examples of Western blots showing 
PON2 (isoform 2, 43 kDa) expression for the same three placentas are also shown in 
Figure 17 (blots D-F). Friedman test analysis showed there was no difference in expression 
of either isoform between the three sites (inner, middle, outer) within individual placentas. 
The graphs for blots A-C (isoform 1, 62 kDa) are shown in Figure 18 (A-C) and the graphs 
for blots D-F (isoform 2, 43 kDa) are shown in Figure 3-2 (D-F). 
 
 
Figure 3-1: Western blots showing PON2 expression in inner, middle and outer sites of 
three individual placentas (non-labour group). Four quadrants were sampled in each zone. 
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A, B and C show the 62 kDa isoform 1 for the three placentas shown in Figure 17.   D, E 
and F show the 43 kDa isoform 2 for the same three placentas also shown in Figure 17. 
 
 
 
 
Figure 3-2: Graphs show median and interquartile range for PON2 isoforms 1 and 2 for the 
combined 4 quadrants sampled in the inner, middle and outer zones of three different 
placentas (A-C, D-F non-labour group) shown in Figure 17. Comparison between zones 
was performed using Friedman analysis. 
 
Experiment 2: This experiment was designed to test if there was a spatial difference in 
expression of PON2 within individual placentas obtained from women who were in labour. 
Two isoforms (62 kDa and 43 kDa) were also identified in all placenta samples. Examples 
of Western blots showing PON2 (isoform 1, 62 kDa) expression for 3 different placentas 
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(all labour) are shown in Figure 3-3 (blots A-C). Examples of Western blots showing 
PON2 (isoform 2, 43 kDa) expression for the same three placentas are also shown in 
Figure 19 (blots D-F). Friedman test analysis showed there was also no difference in 
expression of either isoform between the three sites (inner, middle, outer). The graphs for 
blots A-C (isoform 1, 62 kDa) are shown in Figure 20 (A-C) and the graphs for blots 
(isoform 2, 43 kDa) are shown in Figure 3-4 (D-F). 
 
Figure 3-3: Western blots showing PON2 expression in inner, middle and outer sites of 
three individual placentas (labour group). Four quadrants were sampled in each zone. A, B 
and C show the 62 kDa isoform 1. D, E and F show the 43 kDa isoform 2. 
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Figure 3-4: Graphs show median and interquartile range for the 4 quadrants sampled in the 
inner, middle and outer zones of each of the three placentas (labour group) shown in Figure 
19. Comparison between zones was performed using Friedman analysis. 
 
 In summary for experiment 1 and 2, there was no spatial difference in expression of either 
PON2 isoform within individual placentas both in non-labour and in labour groups. 
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Experiment 3: This experiment was designed to test if there was any difference in PON2 
expression between labour and non-labour groups at the inner, middle or outer areas of 
placentas. Western blots showing placental PON2 expression in non-labour and labour at 
the inner site are shown in Figure 3-5 (upper panel 62 kDa isoform 1; lower panel 43 kDa 
isoform 2). The graphs and statistical analysis are shown below the blots. No differences 
were found. 
 
 
Figure 3-5: Western blots showing PON2 62 kDa isoform 1 (upper panel) and PON2 43 
kDa isoform 2 (lower panel) expressions in the inner placental site in non-labour and 
labour (n=6 in each group). The graphs show the box and whiskers analysis of the blots. 
Comparison between zones was performed using Mann-Whitney analysis. Graph A, 62 
kDa isoform 1; Graph B, 43 kDa isoform 2. NLG non-labour group, LG labour group. 
 
 
Western blots showing placental PON2 expression in non-labour and labour at the middle 
site are shown in Figure 3-6 (upper panel 62 kDa isoform 1; lower panel 43 kDa isoform 
2). The graphs and statistical analysis are shown below the blots. There was a highly 
significant decrease in PON2 expression in the labour group when compared to the non-
  62 
 
labour group for both the 62 kDa isoform 1, (p=0.02) and the 43 kDa isoform 2, (p=0.006).  
 
 
Figure 3-6: Western blots showing PON2 62 kDa isoform 1 (upper panel) and PON2 43 
kDa isoform 2 (lower panel) expressions in the middle placental site in non-labour and 
labour (n=6 in each group). The graphs show the box and whiskers analysis of the blots. 
Comparison between zones was performed using Mann-Whitney analysis. Graph A, 62 
kDa isoform 1; Graph B, 43 kDa isoform 2. NLG non-labour group, LG labour group. 
 
 
Western blots showing placental PON2 expression in non-labour and labour at the outer 
placental site are shown in Figure 3-7 (upper panel 62 kDa isoform 1; lower panel 43 kDa 
isoform 2). The graphs and statistical analysis are shown below the blots. No differences 
were found. 
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Figure 3-7: Western blots showing PON2 62 kDa isoform 1 (upper panel) and PON2 43 
kDa isoform 2 (lower panel) expressions in the outer site in non-labour and labour (n=6 in 
each group). The graphs show the box and whiskers analysis of the blots. Comparison 
between zones was performed using Mann-Whitney analysis. Graph A, 62 kDa isoform 1; 
Graph B, 43 kDa isoform 2. NLG non-labour group, LG labour group. 
 
 
Experiment 4: This experiment was designed to test if there were any differences in PON2 
mRNA expression within individual placentas at different zones in either labour or non-
labour. Figure 3-8 shows the PON2 RQ values in the inner, middle and outer zones for non 
labour (A) and labour (B).  Just as for both PON2 protein isoforms, no spatial differences 
were found at the mRNA level in either labour or non-labour.  
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Figure 3-8: RQ values for mRNA measurements in inner, middle and outer placental sites 
within individual placentas. A non-labour and B labour. Comparison between zones was 
performed using Friedman analysis. 
 
Experiment 5 was designed to test whether there was any difference between labour and 
non-labour at the inner, middle our outer sites of PON2 at the mRNA level. The results are 
shown in Figure 3-9. As for PON2 protein no differences were found between labour and 
non-labour at the inner or outer placental sites. There was, paradoxically, an increase in 
PON2 mRNA in the labour group at the middle site. 
 
 
Figure 3-9: RQ values for mRNA measurements in inner (A), middle (B) and outer (C) 
placental sites for labour compared with non-labour. Comparison between zones was 
performed using Mann-Whitney analysis. 
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3.2 PON2 expression in pre-eclampsia placentas 
Experiment 1: This experiment was designed to test if there was any difference in PON2 
expression between non-labour control and non-labour PE groups at the inner, middle or 
outer sites of placentas. Western blots showing placental PON2 expression in non-labour 
control and non-labour PE at the inner site are shown in Figure 3-10 (upper panel 62 kDa 
isoform 1; lower panel 43 kDa isoform 2). The graphs and statistical analysis are shown 
below the blots. No differences were found. 
 
Figure 3-10: Western blots showing PON2 62 kDa isoform 1 (upper panel) and PON2 43 
kDa isoform 2 (lower panel) expressions in the inner placental site in non-labour control 
(n=6) and non-labour PE (n=3). The graphs show the box and whiskers analysis of the 
blots. Comparison between zones was performed using Mann Whitney analysis. Graph A, 
62 kDa isoform 1; Graph B, 43 kDa isoform 2. NLG-C (non-labour control group), NLG-
PE (non-labour pre-eclampsia group). 
 
Western blots showing placental PON2 expression in non-labour control and non-labour 
PE at the middle site are shown in Figure 3-11 (upper panel 62 kDa isoform 1; lower panel 
43 kDa isoform 2). The graphs and statistical analysis are shown below the blots. There 
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was a highly significant decrease in PON2 expression in the non-labour PE group when 
compared to the non-labour control group for both the 62 kDa isoform 1, (p=0.02) and the 
43 kDa isoform 2, (p=0.02). Figure 3-12 shows an example of β-actin analysis. Shown are 
the same samples used in Figure 3-11. There was no difference between the non-labour 
control and non-labour PE groups despite the reduction in the PON2 in the non-labour PE 
group. 
 
Figure 3-11: Western blots showing PON2 62 kDa isoform 1 (upper panel) and PON2 43 
kDa isoform 2 (lower panel) expressions in the middle placental site in non-labour control 
(n=6) and non-labour PE (n=3). The graphs show the box and whiskers analysis of the 
blots. Comparison between zones was performed using Mann Whitney analysis. Graph A, 
62 kDa isoform 1; Graph B, 43 kDa isoform 2. NLG-C (non-labour control group), NLG-
PE (non-labour PE group). 
 
Β-actin is expressed in cells and is commonly used as a reference for loading. It is 
important to adjust the sample reading (western blot protocol) to for any observed changes 
in β actin protein levels. The equality of loading was tested by using actin-β as a loading 
control. Western blot showing actin-β expression in the non-labour control and non-labour 
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PE at the middle site are shown in figure 3-12. No differences were found between β actin 
in the groups compared in this thesis.   
 
 
 
Figure 3-12: Western blots showing actin-β antibody as loading control to compare the 
same placenta samples in Figure 27. Non-labour control group compared to the non-labour 
PE group at the middle site. 
 
Western blots showing placental PON2 expression in non-labour control and non-labour 
PE at the outer site are shown in Figure 3-13 (upper panel 62 kDa isoform 1; lower panel 
43 kDa isoform 2). The graphs and statistical analysis are shown below the blots. No 
differences were found. 
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Figure 3-13:  Western blots showing PON2 62 kDa isoform 1 (upper panel) and PON2 43 
kDa isoform 2 (lower panel) expressions in the outer placental site in non-labour control 
(n=6) and non-labour PE (n=5). The graphs show the box and whiskers analysis of the 
blots. Comparison between zones was performed using Mann Whitney analysis. Graph A, 
62 kDa isoform 1; Graph B, 43 kDa isoform 2. NLG-C (non-labour control group), NLG-
PE (non-labour PE group). 
 
 
Experiment 2: This experiment was designed to test if there was any difference in PON2 
expression between labour control and labour PE groups at the inner, middle or outer sites 
of placentas. Western blots showing placental PON2 expression in labour control and 
labour PE at the inner site are shown in Figure 3-14 (upper panel 62 kDa isoform 1; lower 
panel 43 kDa isoform 2). The graphs and statistical analysis are shown below the blots. No 
differences were found. 
 
 
Figure 3-14: Western blots showing PON2 62 kDa isoform 1 (upper panel) and PON2 43 
kDa isoform 2 (lower panel) expressions in the inner placental site in labour control (n=6) 
and labour PE (n=7). The graphs show the box and whiskers analysis of the blots. 
Comparison between zones was performed using Mann Whitney analysis. Graph A, 62 
kDa isoform 1; Graph B, 43 kDa isoform 2. LG-C labour control group, LG-PE labour pre-
eclampsia group. 
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Western blots showing placental PON2 expression in labour control and labour PE at the 
middle site are shown in Figure 3-15 (upper panel 62 kDa isoform 1; lower panel 43 kDa 
isoform 2). The graphs and statistical analysis are shown below the blots. There was a 
highly significant decrease in PON2 expression in the labour PE group when compared to 
the non-labour control group for both the 62 kDa isoform 1, (p=0.008) and the 43 kDa 
isoform 2, (p=0.001). Figure 3-15 shows an example of β-actin analysis. Shown are the 
same samples used in Figure 29. There was no difference between the labour control and 
labour PE groups despite the reduction in the PON2 in the labour PE group. 
 
 
Figure 3-15: Western blots showing PON2 62 kDa isoform 1 (upper panel) and PON2 43 
kDa isoform 2 (lower panel) expressions in the middle placental site in labour control 
(n=6) and labour PE (n=7). The graphs show the box and whiskers analysis of the blots. 
Comparison between zones was performed using Mann Whitney analysis. Graph A, 62 
kDa isoform 1; Graph B, 43 kDa isoform 2. LG-C labour control group, LG-PE labour PE 
group. 
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The equality of loading was tested by using actin-β as a loading control. Western blot 
showing actin-β expression in the labour control and labour PE at the middle site are 
shown in figure 3-16. 
 
 
Figure 3-16: Western blots showing actin-β antibody as loading control to compare the 
same placenta samples in Figure 29. Labour control group compared to the labour PE 
group at the middle site. 
 
Western blots showing placental PON2 expression in labour control and labour PE at the 
outer site are shown in Figure 3-15 (upper panel 62 kDa isoform 1; lower panel 43 kDa 
isoform 2). The graphs and statistical analysis are shown below the blots. No differences 
were found. 
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Figure 3-17:  Western blots showing PON2 62 kDa isoform 1 (upper panel) and PON2 43 
kDa isoform 2 (lower panel) expressions in the outer placental site in labour control (n=6) 
and labour PE (n=6). The graphs show the box and whiskers analysis of the blots. 
Comparison between zones was performed using Mann Whitney analysis. Graph A, 62 
kDa isoform 1; Graph B, 43 kDa isoform 2. LG-C labour control group, LG-PE labour PE 
group. 
 
 
Experiment 3: This experiment was designed to test whether there was any difference 
between non-labour control and non-labour PE at the inner and middle sites at the PON2 
mRNA level. The results are shown in Figure 3-16. No differences were found at both 
inner and middle sites. 
 
 
Figure 3-18: RQ values for PON2 mRNA measurements in inner and middle placental sites 
for non-labour control compared with non-labour PE. Comparison between zones was 
performed using Mann-Whitney analysis. 
 
Experiment 4: This experiment was designed to test whether there was any difference 
between labour controls and labour PE at the inner and middle sites at the PON2 mRNA 
level. The results are shown in Figure 3-17. No differences were found at both inner and 
middle sites. 
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Figure 3-19: RQ values for PON2 mRNA measurements in inner and middle placental sites 
for labour control compared with labour PE. Comparison between zones was performed 
using Mann-Whitney analysis. 
 
Experiment 5: This experiment was designed to test whether there was any difference 
between normotensive pregnancies and pregnancy complicated with pre-eclampsia at the 
inner and middle sites at the PON2 mRNA level. The results are shown in Figure3-18. 
There was no significant difference at inner and middle sites. 
 
 
Figure 3-20: RQ values for PON2 mRNA measurements in inner and middle placental sites 
for normotensive pregnancy compared with pregnancy complicated with pre-eclampsia. 
Comparison between zones was performed using Mann-Whitney analysis. 
 
 
 
  73 
 
3.3 PON2 expression in ischemic-reperfusion tissue 
cultural experiment 
Due to time constraints only one set of experiments was performed for all of the below. 
The aim was to determine whether pilot data from this group of experiments revealed any 
data suggesting that more experiments were warranted. 
Experiment 1: This experiment involved exposing placenta samples to 2% O2 (hypoxia) for 
one hour and then 8% O2 (normoxia). The control samples were exposed to 8% O2 
(normoxia). Four lengths of time points (3, 6, 12 and 22 hours) were used for re-
oxygenation. PON2 protein expression was investigated using Western blot analysis. 
PON2 mRNA was investigated using RT-qPCR. Statistical analysis was performed using 
the Minitab 17 package and the two way ANOVA test was used. Interaction plot were 
plotted out to demonstrate the findings. Two PON2 isoforms (62 kDa and 43 kDa) were 
identified. Examples of Western blots showing PON2 (isoform 1, 62 kDa and isoform 2, 
43 kDa) expression for the set of experiments performed on placental tissue obtained from 
the inner site are shown in Figure 3-19. Two ways ANOVA analysis showed there was no 
significant difference in expression of either isoform 1 and 2 due to hypoxia reperfusion 
(p=0.6, p=0.8 respectively for both isoforms) at the inner site Figure 3-20. It was 
interesting that expression of PON2 was reduced in both groups, perhaps due to protein 
turnover.  
 
Figure 3-21: Western blots showing PON2 62 kDa isoform 1 (upper panel) and PON2 43 
kDa isoform 2 (lower panel) expressions in the inner placental site. Ref 1 represents the 
sample collected in the labour suite; Ref 2 represents the sample after transfer to the 
laboratory. Different time points (3, 6, 12 and 22 hours) for the tissues following exposure 
to hypoxia then normoxia (E) are shown. Control tissue exposed to normoxia only for the 
same times are indicated as with C. 
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Figure 3-22: The graphs show the interaction plots analysis for PON2 protein expression at 
the inner site. The graph shows data of the samples exposing to hypoxia reperfusion (Red 
dotted line, YES) compared to the control samples (Blue continuous line, NO) at different 
time points. Upper panel isoform 1, lower panel isoform 2. Hypoxia-Rep ((hypoxia-
Reperfusion). O2 (oxygen). 
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Experiment 2: This experiment was the same as the above experiment 1 but this time the 
middle area of the placenta was exposed to hypoxia-reperfusion. Two PON2 isoforms (62 
kDa and 43 kDa) were identified again in all samples. Examples of Western blots showing 
PON2 (isoform 1, 62 kDa and isoform 2, 43 kDa) expression for middle site are shown in 
Figure 3-21. For hypoxia-reperfusion for comparison of paired points there was also no 
difference for both isoforms (isoform1 p=0.1, isoform 2 p=0.9 respectively). The 
interaction plot is shown in Figure 3-22. Again expression of PON2 was reduced in both 
groups with increasing time, perhaps due to protein turnover. 
 
 
Figure 3-23: Western blots showing PON2 62 kDa isoform 1 (upper panel) and PON2 43 
kDa isoform 2 (lower panel) expressions in the middle placental site. Ref 1 is the sample 
collected in the labour suite. Ref 2 is the sample once transferred to the laboratory. 
Different time points (3, 6, 12 and 22 hours) for the tissues following exposure to hypoxia 
then normoxia (E) are shown. Control tissue exposed to normoxia only for the same times 
are indicated as with C.  
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Figure 3-24: The graphs show the interaction plots analysis for PON2 protein expression at 
the middle site. The graph shows data of the samples exposing to hypoxia reperfusion (Red 
dotted line, YES) compared to the control samples (Blue continuous line, NO) at different 
time points. Upper panel isoform 1, lower panel isoform 2. Hypoxia-Rep ((hypoxia-
Reperfusion). O2 (oxygen). 
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Experiment 3: This experiment was the same as the above experiment 1 but this time the 
outer site of the placenta was exposed to hypoxia-reperfusion. Two PON2 isoforms (62 
kDa and 43 kDa) were identified again in all samples Figure 3-23. Two way ANOVA 
analysis showed there was no significant difference in expression of either isoform 1 and 2 
due to hypoxia then reperfusion (p=0.9 isoform 1, p=0.3 isoform 2) at the outer site. The 
interaction blot is shown in Figure 3-24. Again expression of PON2 was reduced in both 
groups, perhaps due to protein turnover. 
 
 
Figure 3-25: Western blots showing PON2 62 kDa isoform 1 (upper panel) and PON2 43 
kDa isoform 2 (lower panel) expressions in the outer placental site. Ref 1 is the sample 
collected in the labour suite. Ref 2 is the sample collected once transferred to the 
laboratory. Different time points (3, 6, 12 and 22 hours) for the tissues following exposure 
to hypoxia then normoxia (E) are shown. Control tissue exposed to normoxia only for the 
same times are indicated as with C.  
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Figure 3-26: The graph shows the interaction plot analysis of the data for PON2 protein 
expression at the outer site. The graph shows data of the samples exposing to hypoxia 
reperfusion (Red dotted line, YES) compared to the control samples (Blue continuous line, 
NO) at different time points. Upper panel isoform 1, lower panel isoform 2. Hypoxia-Rep 
((hypoxia-Reperfusion). O2 (oxygen). 
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The following set of data is the same experiment as above but this time mRNA was 
analyzed by RT-PCR. 
 
Experiment 4: This experiment was designed to test if there was any difference in PON2 
mRNA expression between tissues were exposing to hypoxia reperfusion and control at the 
inner site of placentas according to four different time points. There was no significant 
difference in expression of PON2 due to hypoxia reperfusion effect (p=0.4). The 
interaction plot is shown in Figure 3-25. 
 
Figure 3-27: The graphs show the interaction plots analysis of the data for PON2 mRNA at 
the inner site. The graph shows data of the samples exposing to hypoxia reperfusion (Red 
dotted line, YES) compared to the control samples (Blue continuous line, NO) at different 
time points. 
 
Experiment 5: This experiment was designed to test if there was any difference in PON2 
mRNA expression between tissues were exposing to hypoxia reperfusion at the middle site 
of placentas according to four different time points. There was no significant difference in 
expression of PON2 due to hypoxia reperfusion (p=0.3). However at 6 hours the 
experimental group showed a clear increase. This suggests that further experiments to 
increase the number of experiments would then show whether this was a real statistical 
changes.  The interaction blot is shown in Figure 3-26. 
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Figure 3-28: The graphs show the interaction plots analysis of the data for PON2 mRNA at 
the middle site. Graph samples exposing to hypoxia reperfusion (Red dotted line, YES) 
compared to the control samples (Blue continuous line, NO) at different time points. 
 
Experiment 6: This experiment was designed to test if there was any difference in PON2 
mRNA expression between tissues were exposing to hypoxia reperfusion and control at the 
outer site of placentas according to four different time points. There was no significant 
difference in expression of PON2 due to hypoxia reperfusion (p=0.3). However at 6 hours 
the experimental group again showed a clear increase. This suggests that further 
experiments to increase the number of experiments would then show whether this was a 
real statistical changes.  The interaction blot is shown in Figure 3-27. 
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Figure 3-29: The graphs show the interaction plots analysis of the data for PON2 mRNA at 
the outer site. Graph show samples exposed to hypoxia (Red dotted line, YES) compared 
to the control samples (Blue continuous line, NO) at different time points. 
 
 
In summary although these data are very preliminary there was an obvious increase in 
PON2 mRNA in inner, middle and outer placental areas when exposed to hypoxia re-
oxygenation at the 6 hours point. Future experiments should follow this up to determine if 
this is a real statistical effect. 
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3.4 PON3 expression in Labour 
Experiment 1: This experiment was designed to test if there was a spatial difference in 
expression of PON3 within individual placentas obtained from women who were not in 
labour. All samples expressed PON3. Examples of Western blots showing PON3 
expression for 3 different placentas (all non-labour) are shown in Figure 3-28. Friedman 
test analysis showed there was no difference in expression of PON3 between the three sites 
(inner, middle, outer) within individual placentas.  
 
 
Figure 3-30: Western blots showing PON3 expression in inner, middle and outer sites of 
three individual placentas (non-labour group). Four quadrants were sampled in each zone. 
Graphs show the median for PON3. 
 
Experiment 2: This experiment was designed to test if there was a spatial difference in 
expression of PON3 within individual placentas obtained from women who were in labour. 
Examples of Western blots showing PON3 expression for 3 different placentas (labour) are 
shown in Figure 3-29. Friedman test analysis showed there was also no difference in 
expression between the three sites (inner, middle, outer).  
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Figure 3-31: Western blots showing PON3 expression in inner, middle and outer zones of 
three individual placentas (labour group). Four quadrants were sampled in each zone. 
Graphs show the median for PON3 
 
 
Experiment 3: This experiment was designed to test if there was any difference in PON3 
expression between labour and non-labour groups at the inner, middle or outer areas of 
placentas. Western blots showing placental PON3 expression in non-labour and labour at 
the inner, middle and outer zones are shown in Figure 3-30. The graphs and statistical 
analysis are shown below the blots. PON3 was significantly decreased in the labour group 
when compared to the non-labour group at the inner site (p=0.02). No other differences 
were found when comparing the middle and outer sites of non-labour to the labour groups 
(p=0.24, p=0.09). 
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Figure 3-32: Western blots showing PON3 expression in non-labour group compared to the 
labour group at the inner, middle and outer zones. Graphs show the median for PON3. 
  
 
3.5 PON3 expression in Pre-eclampsia 
Experiment 1: This experiment was designed to test if there was any difference in PON3 
expression between non-labour control and non-labour PE groups at the inner or middle 
areas of placentas. Western blots showing placental PON3 expression in non-labour 
control and non-labour PE at the inner site are shown in Figure 3-31. The graphs and 
statistical analysis are shown below the blots. There was a significant decreased in PON3 
expression in the PE non-labour group compared to the control non-labour group in the 
middle sites (p=0.02). However, no difference was found in the inner site (p=0.16). 
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Figure 3-33: Western blots showing PON3 expression in non-labour control compared to 
non-labour PE at the inner and middle zones. Data analysis shows the median for PON3 
expression. 
 
Experiment 2: This experiment was designed to test if there was any difference in PON3 
expression between labour control and labour PE groups at the inner or middle areas of 
placentas. Western blots showing placental PON3 expression in labour control and labour 
PE at the inner site are shown in Figure 3-32. The graphs and statistical analysis are shown 
below the blots. There was a significant decrease in the PE labour group compared to the 
control labour at the middle sites (p=0.04). At the inner there was a trend but not 
significant (p=0.06). 
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Figure 3-34: Western blots showing PON3 expression in labour control compared to labour 
PE at the inner and middle zones. Data analysis shows the median for PON3 expression. 
 
 
3.6 PON3 expression in hypoxia-reperfusion tissue 
cultural experiment 
Experiment 1: This experiment undertaken involved exposing placenta samples to 2% O2 
(hypoxia) for one hour and then 8% O2 (normoxia) compared to the control samples which 
were exposed to only 8% O2 (normoxia) at four time points 3, 6, 12 and 22 hours. PON3 
protein expression was investigated using Western blot analysis. Statistical analysis was 
performed using the Minitab 17 package and the two way ANOVA test was used. 
Interaction plot were plotted out to demonstrate the findings. Western blots showing PON3 
expression for the inner site of placenta sample is shown in Figure 3-33. Two ways 
ANOVA analysis showed there was no significant difference in expression of PON3 due to 
hypoxia reperfusion at the inner site (p=0.8). The interaction plot is shown in Figure 3-33. 
As for the PON2 protein there was a gradual fall with time.
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Figure 3-35: Western blots showing PON3 expression (upper panel) in the inner placental 
zone. Ref 1 is the sample collected in the labour suite. Ref 2 is the sample collected after 
arriving in the laboratory. Different time point (3, 6, 12 and 22 hours) of reperfusion was 
performed. Graphs show the interaction plots analysis of the data for PON3 protein 
expression at the inner site. Samples exposed to hypoxia reperfusion are shown as a (red 
dotted line, YES) and compared to the control samples (Blue continuous line, NO) at 
different time points. 
 
Experiment 2: This experiment was the same as the above but now the middle site of the 
placenta was assessed in its response to hypoxia reperfusion. Example of Western blots 
showing PON3 expression for the inner site of the placenta sample is shown in Figure 3-34 
Two way ANOVA test analysis showed no significant differences (p=0.7). The interaction 
plot is shown in Figure 3-34 below the blots. 
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Figure 3-36: Western blots showing PON3 expression (upper panel) in the middle placental 
site. Ref 1 is the sample collected in the labour suite. Ref 2 is the sample collected after 
arriving in the laboratory. Different time point (3, 6, 12 and 22 hours) of reperfusion was 
performed. Graphs show the interaction plots analysis of the data for PON3 protein 
expression at the middle site. Samples exposed to hypoxia reperfusion are shown as a (red 
dotted line, YES) and compared to the control samples (Blue continuous line, NO) at 
different time points. 
 
Experiment 3: This experiment was designed to test if there was any difference in PON3 
protein expression between tissues following exposing placental samples from the outer 
site to hypoxia reperfusion. Examples of Western blots showing PON3 expression are 
shown in Figure 3-35 Again no difference was found between the two groups (p=0.1 for 
both). The interaction plot is also shown in Figure 3-35. 
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Figure 3-37: Western blots showing PON3 expression (upper panel) in samples from the 
outer placental site. Ref 1 is the sample collected in the labour suite. Ref 2 is the sample 
collected after transport to the laboratory. Different time point (3, 6, 12 and 22 hours) of 
reperfusion was performed. Graphs show the interaction plots analysis of the data for 
PON3 protein expression at the outer site. Samples exposed to hypoxia reperfusion are 
shown as a (red dotted line, YES) and compared to the control samples (Blue continuous 
line, NO) at different time points. 
 
 
3.7 PON3 mRNA expression:  
Although PON3 protein expression was very high at the protein level within placenta 
tissue, the PON3 at mRNA level using TaqMan assay was very low (Ct. Value was more 
than 35 cycle figure 2-8) or no amplification. According to TaqMan gene expression assay 
quality control if Ct value more than 35 cycles this mean that cDNA in the sample less 
than 5 copies. There was no record of PON3 gene being expression in placenta from Gene 
Card web site (Figure 3-36). Several attempts of optimization for TaqMan gene expression 
assay were undertaken include: 
 Concentrated placenta cDNA (Primer Design) was run. 
 Two different PON3 TaqMan gene expression assays (Applied Biosystem, cat no: 
Hs01023629_m1 and cat no: Hs01023630_m1) were used. 
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  Heart and myometrium tissue were investigated for PON3 mRNA gene expression 
  Agarose gel 2% was run on PCR product showed double bands in different 
amplicon length indicated that expression was not PON3 Figure 3-37. 
 
 
 
Figure 3-38: Print screen of Gene Card website showed that PON3 gene expression (red 
cycle) in placenta (black arrows) is so little (red arrow). 
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Figure 3-39: Graph showed qPCR product of PON3 TaqMan gene assay. Double bands 
were identified by run agarose gel at 100-120 bp and the amplicon length for the PON3 
TaqMan gene assay is at the 69 bp. 
 
This placenta, heart and myometrium did not express PON3 mRNA. There is no evidence 
in the literature that PON3 is expressed in heart or myometrium and our study was unable 
to find PON3 in this tissue. One possibility is that PON3 protein could be produced 
elsewhere within the body and then transported to the placenta where it deposits. This 
could account for the very high level detected with Western blots as there is a very high 
blood flow to the placenta. Another possibility is that the protein is extremely stable, while 
the mRNA is very unstable. This would mean that we would need little detectable mRNA 
to build up large deposits of the protein. Also it is important to remember that the mRNA 
level is not always directly comparable to the amount of detectable proteins, as some 
protein may degrade very quickly, while other proteins can be extremely stable. This is 
also true for the mRNA species as well, as some mRNA will be degraded or silenced 
(miRNA) very quickly and some mRNAs will be extremely stable within the cell. In this 
situation, it is more than likely that the results we have seen with TaqMan are the true 
negative results, that there is no detectable level of PON3 mRNA within placenta. 
 
At the end of the results section a summarised table regards the main finding of the study 
was done and is shown in table 3-1. 
  92 
 
 
Table 3-1:  Results summary table 
  
Gene Protein Molecular Hypoxia-reperfusion 
injury  
PON2  No spatial difference across 
individual placenta. 
 
There was a significant 
decrease in labour group 
compared to the non-labour 
group at the middle site only. 
 
 
There was a significant 
decrease in PE group 
compared to the control 
group at the middle site only. 
No spatial difference across 
individual placenta. 
 
There was a significant 
decrease in labour group 
compared to the non-labour 
group at the middle site 
only. 
 
No changes were found. 
There was a clear 
decrease over the time.  
 
There was no significant 
difference after exposed 
to hypoxia-reperfusion 
insult. 
PON3  No spatial difference across 
individual placenta. 
 
There was a significant 
decrease in labour group 
compared to the non-labour 
group at the inner site only. 
 
There was a significant 
decrease in PE group 
compared to the control 
group at the middle site only. 
 
There was no PON3 mRNA 
expression in placenta 
tissue. 
There was a clear 
decrease over the time.  
 
There was no significant 
difference after exposed 
to hypoxia-reperfusion 
insult. 
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4 Discussion 
4.1 PONs and present findings 
PON2 and PON3 expression was significant decreased in labour and further less in pre-
eclampsia group especially at the middle site. As labour is an inflammatory process the 
reduction in PONs would allow the inflammatory pathways to go further and continue as 
natural process. Importantly the present work shows that expression varies on the zone of 
the placenta the piece of tissue is taken from. This has important implications for placental 
research as the overwhelming majority of published papers do not control for sampling 
area. This may, at least in part, explain why there is such a discrepancy in published 
findings for similar studies applied to the placenta. In addition, it seemed odd that for so 
many studies on the placenta, and for any given protein, there seemed to be such a variety 
of conflicting papers. Part of this thesis therefore attempted to try and understand if this 
could, at least in part, be explained by sampling approaches. The present study has 
confirmed that protein expression varied at different areas of the placenta. With regard to 
labour controls or labour pre-eclampsia it is impossible to know what changes in protein 
expression contribute to labour or pre-eclampsia and what protein changes are a result of 
labour or pre-eclampsia. The fact that changes in protein expression are noted across zones 
suggested there is either something different about the inherent physiology of different 
zones of the placenta or it may be that there is something different about the blood supply 
to the different zones. It is beyond the work of this thesis to be able to answer that. 
 
4.1.1 Key findings PON2 
The main findings of this study were that there were no spatial differences within 
individual placentas for both labour and non-labour. At the middle site there was a 
significant decrease in PON2 expression in the labour group when compared to the non-
labour group for both the 62 kDa form (p=0.02) and the 43 kDa form (p=0.006).  
In PE, the main findings were here was no difference between PON2 in the non-labour 
control group compared to the non-labour PE group at the inner placental site or between 
the respective labour groups. A significant reduction in both PON2 isoforms was observed 
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in the non-labour PE group when compared to the non-labour control group and for the 
respective labour groups at the middle site. 
 
The hypoxia-reperfusion experiments are preliminary. But there was an obvious increase in 
PON2 mRNA in inner, middle and outer placental areas when exposed to hypoxia re-
oxygenation at the 6 hours’ time point. Future experiments should follow this up to 
determine if this is a real statistical effect. 
 
 
4.1.2 Key findings PON3 
There was no difference in expression of PON3 between the three sites (inner, middle, 
outer) within individual placentas for both labour and non-labour. PON3 was significantly 
decreased in the labour group when compared to the non-labour group at the inner site.  No 
other differences were found. 
There was a significant decrease in PON3 expression in the PE non-labour group 
compared to the control non-labour group in the middle site only. There was a significant 
decrease in the PE labour group compared to the control labour at the middle site only.  
Again the hypoxia-reperfusion experiments are preliminary but worth pursuing. 
 
 
4.2 Labour and PON 
Normal human labour involves interaction of hormonal, neurological, mechanical stretch 
and inflammatory pathways and the placenta plays a crucial role. Labour has been show to 
induce placental oxidative stress, which in turn activates ER stress in vitro (Yung et al., 
2007; Cindrova-Davies et al., 2007). The paraoxonases are involved in protecting against 
oxidative damage and lipid peroxidation, modulation of endoplasmic reticulum (ER) stress 
and regulation of apoptosis (Martinelli et al., 2012; Li et al., 2014). Until recently nothing 
was known about the role of PONs in the placenta and how expression was affected by the 
stress of labour. This study examined PON2 expression in the placenta during labour and 
has now been published (Alwarfaly et al., 2014). No difference in protein expression of 
either PON2 isoforms was found between the three sites (inner, middle, outer) within 
either the labour or non-labour group. At the middle site there was a highly significant 
decrease in PON2 expression in the labour group when compared to the non-labour group 
  95 
 
for both isoforms. A reduction in PON2 protein may help to initiate or promote labour.  
 
PONs is glycosylated with high-mannose-type sugars, which are important for protein 
stability but are not essential for their enzymatic activities (Martinelli et al., 2012). 
Whether alterations in glycosylation of PON2 could affect PON2 expression in the 
placenta would require future research. In contrast PON3 was significantly decreased in 
the labour group when compared to the non-labour group at the inner site. Whether the site 
of where the reduction of the protein is relevant remains to be discovered nonetheless a 
reduction was also found for PON3 too. There was a significant decrease in PON3 
expression in the PE non-labour group compared to the control non-labour group in the 
middle site only. There was a significant decrease in the PE labour group compared to the 
control labour at the middle site only. Thus PON3 may just as important as PON2. 
 
 
 
4.3 PE general 
PE remains one of the leading causes of maternal morbidity and mortality worldwide for 
both mothers and babies. About 50,000 women die in developing countries per year from 
the disorder (Duley, 1992). The gold standard for management of PE has been the same for 
100 years that is careful maternal observation for the signs of PE and delivery of women 
with symptoms that are severe. Maternal mortality is far less in developed countries due to 
proper perinatal observation; nevertheless morbidity still remains the leading cause of 
admissions to intensive care for pregnant women. (Tang et al., 1997) Delivery of women 
who develop severe PE early in gestation accounts for 8% of all preterm births (Ananth et 
al., 2006). With that come all the problems associated with prematurity. 
 
During the past 20 years, our knowledge of PE has increased greatly. It is known that 
normal pregnancy is a pro-inflammatory state (Redman et al., 1990) which increases in 
normal pregnancy as the pregnancy advances (Duckitt et al., 2005). 
Monocytes/macrophages play an important role (Faas et al., 2014). Redman (1990) has 
proposed therefore that PE is an excessive response to this stress. Women who already 
have an existing inflammatory disorder such as autoimmune disease, renal disease or 
metabolic syndromes are more likely to develop PE which supports the notion that it the 
entire inflammatory system has been pushed beyond which the mother cannot cope 
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(Duckitt et al., 2005). 
 
 
 
4.3.1 Definition of PE 
PE is currently defined as cardiovascular and renal dysfunction identified by blood 
pressure and proteinuria measurements. This is a historical definition coming from the fact 
these were the first observed symptoms in women which were then followed by eclampsia, 
which was then thought to be a pregnancy-specific seizure disorder (Chesley, 1984).  
 
 
4.3.2 Risk 
Hypertension and proteinuria predict increased risk for mother and baby however, even 
without proteinuria, there is an increased risk associated with gestational hypertension 
when accompanied by other systemic involvement. It has been stated that a key feature in 
studying PE is recognizing the fact that it is a syndrome which does not require proteinuria 
(Myatt et al., 2014). 
 
4.3.3 Causes and prediction of PE 
During the past 20 years, our knowledge of PE has increased greatly.  In vivo and in vitro 
(through venous circulation) studies have aided our understanding of the mechanisms 
involved in failed conversion of maternal spiral arteries (Lyall et al., 2013) and that this 
can lead to ischemia-reperfusion injury of the placenta (Burton et al., 2009). Known better 
is the role of inflammation, including endothelial dysfunction and recognizing that it is a 
multisystem disorder (Roberts et al., 1989). This has meant that less importance is put on 
blood pressure as the important contributing factor. The primary organ involvement may 
be hepatic, renal, cardiovascular, or placental. Although this has helped to direct research 
efforts to better understand the aetiology, it has not had a significant effect on how patients 
are managed or indeed how the condition is predicted reliably. One of the most promising 
attempts for prediction was to measure factors (such as placental derived factors) 
implicated in the pathophysiology of PE to try and predict the disorder. None have as yet 
been adopted for use in routine clinical practice due to problems such as adequate 
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sensitivity and specificity (Redman et al., 2014). 
 
Prediction and treatment of PE has been more successful in small studies than larger 
powered multi-centre studies. This has been put down to smaller studies having a more 
homogenous population and conversely larger multi-centre trials having a more 
heterogenous population (Myatt et al., 2014). Another problem of predictive studies is that 
factors being measured are not present in all women with PE (Myatt et al., 2014). All of 
this supports the idea that sub-groups of PE exist which all end up presenting as high blood 
pressure and proteinuria. Indeed this is supported by clinical and epidemiological data.  
 
Placental pathology is generally worse in early onset PE however there is no histological 
evidence that spiral artery remodelling is restricted to early onset disease only (lyall et al., 
2013). There appears to be a spectrum of changes both within all the spiral arteries of 
individual cases and across gestational ages (lyall et al., 2013). Where remodelling is 
defective it has been predicted to result in high-velocity, intermittent, maternal blood flow 
within the inter-villous space (Burton et al., 2009) which can induce placental oxidative 
stress through high shear rates and an ischemia/hypoxia–reperfusion type of injury (Burton 
et al., 2004, Redman et al., 2009). In vitro, placental oxidative stress causes release of anti-
angiogenic factors which may reach the maternal circulation through the venous 
circulation (Cindrova-Davies et al., 2007). The presence of anti-angiogenic factors in the 
maternal circulation during the second trimester of pregnancy, for example sFlt1, is 
strongly positively the onset of PE (Vatten et al., 2007). However the maternal response to 
the deficient remodelling may also determine how well the pregnancy progresses. As well 
as inducing oxidative stress ischemia/hypoxia–reperfusion activates ER stress and 
apoptosis (Vatten et al., 2007).    
 
PONs has been shown, as outlined below, to be involved in ER stress and apoptosis. Thus, 
in theory, a reduction in PON expression such observed in this work, would favour ER 
stress.  Hormones, growth factors and plasma membrane proteins as well as protein post-
translational modification occur in the ER. Knockout mice studies have shown that ER 
stress causes placental insufficiency leading to restriction of fetal development and growth 
(Iwawaki T et al., 2009). Accumulation of unfolded and misfolded proteins activates ER 
stress-response pathways, also referred to as the unfolded protein response (UPR). The 
UPR is made up of three conserved signalling pathways. The first is the PERK–eIF2α 
pathway which attenuates non-essential protein synthesis. The ATF6 and IRE1–XBP1 
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pathways increase folding capacity by up-regulation of the ER chaperones GRP78 and 
GRP94. Furthermore the ER-associated protein degradation pathway facilitates protein 
degradation (Schroder et al., 2005). Activation of ER stress pathways has been 
demonstrated n in PE and fetal growth restriction (Yung et al., 2014). Activation of 
placental UPR and stress-response pathways, including P-IRE1α, ATF6, XBP-1, GRP78 
and GRP94, P-p38/p38 and HSP70, was higher in early-onset PE than in late-onset PE and 
normotensive controls with 34 weeks of gestation being where a clear difference between 
gestations was observed; a different placental sampling method was used to the one in this 
thesis.  Cellular stress and protein unfolding also initiates other protective pathways such 
as the heat shock proteins which aid in folding and degradation of misfolded proteins and 
previous work from out laboratory has shown that heat shock protein 70 and 27 expression 
is spatially distributed in human placenta and selectively upregulated during labour and PE 
(Abdulsid et al., 2013 and 2014). 
 
The majority of PE cases present in the last month of pregnancy. The cases used in our 
study were all late-onset. Women can, however, present at any gestational age with PE that 
can rapidly progresses to life-threatening disease over hours to days yet on other women 
the symptoms can remain the same and not get any worse. The 10% cases that present 
early on are markedly different than those at term (Myatt et al., 2014).  PE presenting 
before 37 weeks of gestation is when most of the small for gestational age babies are born 
and before 37 weeks is when the disorder tends to be more serious (Xiong et al., 2002).  In 
our study birth weight was not different between the PE and control groups. Studies in our 
laboratory are now being performed on placentas from severely growth restricted babies to 
determine if PON2 expression is different. Long–term  health consequences for women 
who have had early on-set PE are different too; epidemiological studies have shown the 
risk of cardiovascular disease in later life with earlier onset PE is 8 to 10 fold (Irgens et al., 
2001; Mongraw-Chaffin et al., 2010) compared to 2 fold when PE presents close to term 
(Bellamyet al., 2007).  
 
Numerous studies have been performed on measuring circulating factors in PE as well as 
assessing expression of a plethora placental factor such as those linked to inflammatory, 
anti-angiogenic, oxidative stress, or ER stress-mediated or other pathways. Whether 
studies such as these, including the present one, might help to categorise PE sub-types or 
helps to understand the disease process remains to be seen. Caution should be used in how 
factors are used to categorise PE because different factors can often be linked to a similar 
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pathway (Myatt et al., 2014). Given that circulating paraoxonases are emerging as unique 
protectors against cardiovascular diseases (Martinelli1 et al., 2012; Li et al., 2014). Future 
studies using ELISA to measure PONs in maternal circulation as predictive markers to 
measure PONs as predictive markers of PE will be of interest. There is one important 
human study; term human infants had more than 6-fold higher umbilical cord serum levels 
of PON3 than preterm (24-28 weeks of gestation) infants (Belteki et al., 2010). 
 
The aetiology of the PE syndrome remains elusive and is pregnancy specific. Delivery of 
the placenta is the only cure and so, for this reason, it is generally thought that the root of 
the disorder lies in the placenta. One of the difficulties in studying PE is that it is a 
heterogenous disorder with a range in the way symptoms present clinically as well as 
heterogeneity in the pathological findings reported within the placenta. (Ohkuchi et al., 
2007; Wikstrom et al., 2006). In recent times more emphasis has been placed on how 
placental samples should be taken to ensure systematic sampling however the majority of 
published studies do not follow such procedures. At present, there are no agreed standards 
for placental sampling or storage of samples or for what minimal accompanying clinical 
information is required for interpretation of the results. However attempts are being made 
to put do this (Burton et al., 2014). Many factors can affect subsequent analysis; these 
include direct clinical and non-clinical factors (Myatt et al., 2014; Burton et al., 2014). 
Ethnicity can have effects on the placenta through genetic variations, diet or other factors. 
Both birth weight and placental weight were reported to be lower in Asian women 
compared to European and Afro-Caribbean ethnic groups, although the fetal/placental ratio 
was not different (perry et al., 1995). Cigarette smoke also has been reported to alter 
placenta structure (Bush et al., 2000) as has alcohol (Burd et al., 2007) which has been 
linked to a reduction in placenta size, reduced blood flow and impaired nutrient transport. 
Body mass index is becoming a more and more serious global health issue and no less so 
in pregnant women. High maternal body mass index is negatively correlated with the fetal: 
placental weight ratio (perry et al., 1995). Maternal obesity is also associated with 
increased oxidative stress in the placenta (Roberts et al., 2009) and with a global reduction 
in DNA methylation (Nomura et al., 2013). Placenta weight increases with maternal 
(Haavaldsen et al 2011) and paternal age.  
 
Study groups have met to try and agree how to classify PE into groups (von Dadelszen et 
al., 2003;  Myatt et al., 2014). Several schemes have been proposed, and the most common 
is to divide cases clinically into early- and late-onset, according to the gestational age at 
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diagnosis or when delivery is necessitated. The majority (90%) of cases are late-onset, 
usually defined as the occurrence after 34 weeks gestational age. Of the two forms, early-
onset is often considered the more severe, as it is associated with a higher rate of 
intrauterine growth restriction (IUGR) and risk of maternal cardiovascular complications 
after delivery ( Paruk and Moodley, 2000;  Dahlstrom  et al., 2008). Moreover, there is a 
greater prevalence of placental lesions indicative of maternal malperfusion (Moldenhauer 
et al., 2003; van der Merwe et al., 2010; Nelson et al., 2014) as confirmed by a recent 
magnetic resonance imaging study (Sohlberg  et al., 2014). In view of these differences, it 
has been proposed that PE can be classified on the basis of the pathophysiology into 
‘placental’ and ‘maternal’ causation (Redman et al., 2000).  In the former, it is postulated 
that malperfusion leads to placental stress and the release of cytokines and angiogenic 
regulators that cause maternal endothelial cell activation. In the latter, it is believed that the 
same final stage is reached due to a predisposing exaggerated maternal endothelial 
sensitivity to factors emanating from a relatively normal or excessively large placenta. The 
latter classification is based on normal pregnancy being a pro-inflammatory state, with 
activation of circulating immune cells (Redman et al., 2003) and elevated systemic 
oxidative stress as gestation advances (Belo et al., 2004). Therefore, ‘maternal’ PE has 
been suggested to be an excessive maternal response towards existing inflammation 
(Redman et al., 1999). This is backed up by a growing body of evidence showing that 
women with chronic systemic inflammation, due to conditions such as renal disease, 
autoimmune diseases or metabolic syndromes, have an increased risk of developing PE 
near to term (Duckitt et al., 2005).   
 
In placental PE there is deficient remodelling of the maternal spiral arteries 
(Papageorghiou  et al., 2001; Lyall et al., 2013) shown by abnormal uterine artery Doppler 
waveforms and immunohistochemical analysis of placental bed spiral arteries This is 
thought to result in high-velocity, intermittent, maternal blood flow within the inter-villous 
space (Burton  et al.,  2009) which can induce placental oxidative stress as a result of high 
shear rates leading to an ischaemia/hypoxia–reperfusion type of injury (Burton et al., 2004; 
Redman , Sargent, 2009). Placental oxidative stress causes release of anti-angiogenic 
factors into the maternal circulation (Cindrova-Davies et al., 2007) in the maternal 
circulation during the second trimester of pregnancy levels of anti-angiogenic factors, such 
as sFlt1, positively correlate with onset of the syndrome (Vatten et al., 2007).   
 
The ER is where synthesis of polypeptide hormones, growth factors and plasma membrane 
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proteins and their post-translational modification takes place. Ischaemia/hypoxia–
reperfusion induces oxidative stress and activates ER stress (Yung et al., 2007; Yung et al. 
2008). It has been shown using genetic manipulation studies that ER stress causes placental 
insufficiency, which in turn reduces fetal growth and development (Iwawaki  et al., 2009). 
Accumulation of unfolded and misfolded proteins activates ER stress-response pathways 
and the unfolded protein response pathway (UPR). The UPR comprises three signalling 
pathways: the PERK–eIF2α pathway, which attenuates non-essential protein synthesis; and 
the ATF6 and IRE1–XBP1 pathways, which increase folding capacity by up-regulation of 
the ER chaperones GRP78 and GRP94 and phospholipid biosynthesis. In addition, the ER-
associated protein degradation (ERAD) pathway facilitates protein degradation (Schroder 
and Kaufman, 2005). ER stress pathways in placentae from cases of fetal growth 
restriction show greater activation of ER stress compared to pregnancies complicated with 
PE and fetal growth restriction (Yung et al., 2008). More recently researchers have 
discussed separating findings based on gestational age at diagnosis and/or delivery.  There 
is no agreement what this should be. 
 
 PE is commonly divided into early-onset (<34 weeks) and late-onset (≥34 weeks). As 
stated above researchers are now discussing the distinction between placental and maternal 
PE. It has been suggested placental cases are more likely to be early-onset with fetal 
growth restriction. Activation of placental UPR and stress-response pathways were shown 
to be higher in early-onset PE than in both late-onset PE and normotensive controls 
(NTCs) with 34 weeks of gestation being where a clear distinction was apparent.  In that 
study there was no difference in placentas from ≥ 34 weeks PE and controls were 
indistinguishable. In vitro hypoxia-reoxygenation induced activation of UPR pathways in 
BeWo cells. The authors suggested that placental stress they had studied may be unlikely 
to be involved in late-onset PE however   (Yung et al., 2014). However there are many 
papers in the literature showing stress pathways altering in late-onset PE as discussed 
herein. 
  
4.4 Linking PON2 expression to oxidative stress and 
ischemia-reperfusion injury 
Oxidative stress occurs when the production of reactive oxygen species overwhelms the 
intrinsic anti-oxidant defences. Whether reductions in PON2 protein expression in the 
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placenta contribute to labour and PE or are a result of contractions or placental stress 
cannot be answered since human patients have been used. Contraction of the uterus leads 
to ischemic-reperfusion injury that can alter placental protein expression (CindrovaDavies 
at al., 2007). Furthermore Doppler ultrasound studies have been used to demonstrate an 
inverse relationship between uterine artery resistance and the intensity of uterine 
contractions during labour. In pregnant rhesus monkeys placental blood flow is almost 
completely stopped during sustained myometrium contractions as a result of compression 
of the arcuate and spiral arteries. The closest human model to this was performed on 
patients prior to termination of pregnancy at 17–20 weeks of gestation.  
 
During oxytocin-induced contractions, a 50% reduction in flow into the intervillous space, 
as well as a fall in entry sites and volume, was found compared to when no contractions 
occurred (Borell et al 1965; Ramsey et al., 1980).  This suggests that intermittent perfusion 
of the intervillous space would lead to an ischemic-reperfusion injury of the placenta 
which could affect reactive oxygen species and the oxidant/antioxidant balance (McCord, 
1993). In keeping with this labour has been reported to be associated with placental 
alterations in several pathways linked to oxidative stress and this includes late-onset PE 
(Many et al., 1997; Elliott et al., 1998; Allport et al., 2001; Sitras  et al., 2008; Lee et al., 
2010; Peng et al., 2011; Lim et al., 2012). Other studies from our laboratory have shown 
selective up regulation of heat shock proteins HSP70 and 27 in labour and PE suggesting a 
link to placental oxidative stress (Abdulsid et al., 2013 and 2014). Failure to modify spiral 
arteries is a feature of many cases of PE (Lyall et al., 2013). Some are partially remodelled, 
some fully remodelled and some not remodelled at all. Hence another parameter that could 
potentially affect PON expression might be linked to the physiological remodelled state of 
the spiral artery that supplies a particular area of the placenta.  
 
 
4.5 PONS 
The paraoxonases were named so because the substrate for PON1 is paraoxon which is 
the active metabolite of the organophosphorus insecticide parathion. PON2 and 3 lack 
this esterase activity despite the similar nomenclature. PON1 and PON3 proteins are 
present in plasma and reside in the HDL fraction and protect against oxidative stress by 
hydrolysing certain oxidized lipids in lipoproteins, macrophages, and atherosclerotic 
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lesions (Mackness et al., 1997; Reddy et al., 2001; Jaouad et al., 2006; Sierksma et al., 
2007). Paraoxonases are important detoxifying and anti-oxidative enzymes with roles 
being described in organophosphate poisoning, diabetes, obesity, cardiovascular diseases, 
and innate immunity and with atherosclerosis (Shih et al., 1998; Ng et al., 2006; Shih  et 
al.,  2007; Camps J  et al.,  2009; Shih et al., 2009). 
 
 
4.6 PON2 and cell death 
ER stress activates the UPR pathway and pro-apoptotic CHOP protein in the presence of 
overwhelming ER stress (Oyadomari and Mori, 2004; Zhang et al., 2006; Song et al., 
2008). Mitochondria also play a key role in cell death via production of excess reactive 
oxygen species. (Ott  et al., 2007).  It has been shown that human PON2 diminished not 
only R reactive oxygen species but also ER stress-induced apoptosis in vascular cells 
(Horke et al., 2007). PON2 is expressed in several tissues with antioxidant properties. It 
is capable of preventing cell-mediated oxidative modification of low density lipoprotein 
and ER stress-induced apoptosis. (Ramsey et al., 1980; Cindrova-Davies et al.,  2007; 
Roberts and Hubel, 2009). PON2 is not present in serum lipoprotein fractions but exists 
as an intracellular protein found in almost every tissue, particularly at the perinuclear 
region, ER and mitochondria (Ng et al., 2001; Horke et al., 2007; Rothem et al., 2007). 
Natural substrates remain unknown albeit PON2, as part of the innate immune system, 
appears involved in the defence against infections by the human pathogen Pseudomonas 
aeruginosa (Rothem et al., 2007).  Several studies demonstrated that PON2 protected 
macrophages, vascular and other cells against oxidative stress, whereas its down 
regulation reversed this effect (Ng et al., 2001;  Aviram  et al., 2004; Horke et al., 2007). 
 
PON2 has been shown to be overexpressed in several cancers and it has been suggested 
that this may be due to the fact that PON2 confers resistance to apoptosis as well as 
oxidative stress (Witte et al., 2011). It has been shown that during ER stress, high levels 
of PON2 lowered redox-triggered induction of pro-apoptotic CHOP particularly via the 
JNK pathway, which prevented mitochondrial cell death signalling (Witte et al., 2011).  
Apart from CHOP, PON2 also diminished intrinsic apoptosis as it prevented 
mitochondrial superoxide formation, cardiolipin peroxidation, cytochrome c release, and 
caspase activation. Oxidized lipids can also induce pro-inflammatory genes, such as 
TNF-α and MCP-1, via NF-κB activation (Witte et al., 2011).  Therefore one possibility 
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is that less placental PON2 would result in more oxidized lipids and more NF-κB 
activation which would promote inflammatory responses. Interestingly macrophages 
harvested from PON2-/- mice are more susceptible to cellular oxidative stress than wild-
type macrophages (Fuhrman et al., 2008).  
 
The mechanism by which PON2 modulates ROS production is still unclear (Meilin et 
al., 2010; Altenhöfer et al., 2010; Devarajan et al., 2011). Lactones have been 
suggested to be the natural substrates of PON2 and PON2 lactonase activity has been 
shown to correlate with this enzyme's biological antioxidant properties. Studies have 
shown increased risk of coronary artery disease, carotid atherosclerosis and stroke in 
patients with low paraoxonase activity (Chen et al., 2004). Since PE is a cardiovascular 
disorder future studies in PE include measurement of PONs enzyme activities are 
warranted. Specific gene polymorphisms for PON1 and PON2 have been reported in 
children born pre-term. (Chen et al., 2004).  
 
 
In conclusion this is the first study to investigate the expression of PON2 in PE and there 
are the summary of the results:  
1. PON2 
There were expression of two isoform of PON2; isoform one (62 kDa) and isoform two 
(43 kDa) in all placenta samples. There was no significant difference in spatial expression 
of PON2 protein and mRNA of both isoforms across individual placenta of both labour and 
non-labour groups. There was no significant difference in PON2 protein and mRNA 
expressions of both isoforms between labour and non-labour groups at the inner and outer 
placenta sites. There was a significant decrease in PON2 protein and mRNA expressions of 
both isoform in labour group compared to the non-labour group at the middle site. There 
was no significant difference in PON2 protein expression of both isoforms between non-
labour and labour controls when compared to non-labour and labour PE at the inner 
placenta site. There was a significant decrease in PON2 protein expressions of both 
isoform in non-labour and labour PE groups when compared to the non-labour and labour 
controls group at the middle site. No changes were found in the mRNA level when non-
labour and labour control compared to the non-labour and labour PE. There was no 
significant difference when all normotensive groups compared to the PE groups. 
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2. PON2 expression after hypoxia-reperfusion insult 
There was clear decrease in PON2 expression over the time. There was no significant 
difference in PON2 protein expression of both isoforms at inner, middle and outer 
placental sites after exposed to hypoxia reperfusion injury. There was a clear increase of 
PON2 mRNA in exposed group between 3-12 hours at the middle and outer sites but as it 
was a pilot study so there was no comparison. 
3. PON3 expression 
There was no PON3 mRNA expression in placenta tissue. There was no significant 
difference in spatial expression of PON3 protein across individual placenta of both labour 
and non-labour groups. There was a significant decrease in PON3 protein expressions in 
labour group compared to the non-labour group only at the inner site. There was a 
significant decrease in PON3 protein expressions in non-labour and labour PE group 
compared to the non-labour and labour control group at the middle site. 
 
4. PON3 expression after hypoxia-reperfusion insult 
There was clear decrease in PON2 expression over the time. There was no significant 
difference in PON3 protein expression at inner, middle and outer placental sites after 
exposed to hypoxia reperfusion injury. 
The findings suggest, given the protective roles of paraoxonases, that future studies include 
clinical trials of therapeutic approaches that emerge to increase PONs activity may provide 
a novel of preventing PE and reveal new insights into our understanding of PE. Our 
findings also emphasise the heterogeneity of the placenta.  
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